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Résumé 
 
L’implication des cellules souches cancéreuses (CSCs), aussi connues sous le nom de cellules 
initiatrices de tumeurs (TICs), dans l’initiation, la progression et la récurrence tumorale est un 
concept qui commence à prendre de l’ampleur. Les capacités d’auto-renouvellement et de 
division asymétrique des CSCs pourraient, en effet, expliquer l’hétérogénéité observée au sein 
des tumeurs. En outre, ces cellules seraient également responsables de la formation des 
métastases et de résistances aux chimiothérapies et à la radiothérapie (notamment via une 
entrée en quiescence). Le métabolisme de l’hyaluronan (HA) et un environnement pauvre en 
oxygène, l’hypoxie, sont deux facteurs impliqués dans la constitution d’une niche pour les 
CSCs et dans la progression tumorale. Ce travail est destiné à explorer la contribution de ces 
deux facteurs dans le développement de CSCs au sein de deux lignées cellulaires de cancer du 
sein, l’une (MCF-7) portant des récepteurs à estrogène et l’autre (MDA-MB-231) pas. Le 
modèle utilisé est celui des mammosphères (MSs), ou culture en conditions non adhérentes et 
en milieu défini, qui permet d’enrichir la population cellulaire en CSCs/TICs mais qui est 
également représentatif de l’hétérogénéité des tumeurs in vivo. L’étude a montré que 
l’hypoxie modifie la morphologie des MSs et le métabolisme de l’HA dans la lignée la plus 
agressive, MDA-MB-231, alors qu’elle accélère la croissance des MSs dans la lignée la moins 
agressive, MCF-7. L’interaction entre hypoxie et métabolisme de l’HA devrait être explorée 
plus en profondeur. 
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I. Abbreviations 
 
ABC transporter ATP-binidng cassette transporter 
ALDH Aldehyde dehydrogenase 
ARNT Aryl hydrocarbon receptor nuclear translocator 
ATP Adenosine triphosphate 
BC Breast Cancer 
BMP Bone morphogenetic protein 
CD44s Standard CD44 isoform 
CD44v Variable CD44 isoform 
cDNA complementary DNA 
CpG Cytosine phosphate guanine 
CSC Cancer stem cell 
Da Dalton 
DLA DIGE labelling buffer 
DMEM Dulbecco's modified eagle medium 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide 
ECM Extra cellular matrix 
EMT Epithelial mesenchymal transition 
FACS Fluorescence assisted cell sorting assay 
FBS Fœtal bovine serum 
GAG Glycosaminoglycan 
GLUT1 Glucose transporter 1 
GTPase Guanosine triphosphate hydrolase 
HA Hyaluronic acid or hyaluronan 
HAS Hyaluronic acid synthase 
HAS1 Hyaluronic acid synthase 1 
HAS2 Hyaluronic acid synthase 2 
HAS3 Hyaluronic acid synthase 3 
HIF Hypoxia-inducible factor 
HIF-1α Hypoxia-inducible factor 1α 
HIF-2α Hypoxia-inducible factor 2α 
HRE Hypoxia response element 
HRP Horseradish peroxidase 
HYAL Hyaluronidase 
HYAL1 Hyaluronidase 1 
HYAL2 Hyaluronidase 2 
HYAL3 Hyaluronidase 3 
HYAL4 Hyaluronidase 4 
iPSC Induced pluripotent stem cells 
LDH Lactate dehydrogenase 
MS Mammosphere 
PBS Phosphate buffered saline 
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PHD Prolyl hydroxylase domain 
PI3K Phosphatidylinositol 3-kinase  
PKC Protein kinase C 
PVDF Polyvinylidene fluoride 
pVHL Von Hippel-Lindau tumour suppressor 
RHAMM Hyaluronan-mediated motility receptor 
RNA Ribonucleic acid 
RNase Ribonuclease 
ROS Reactive oxygen species 
RTase Reverse transcriptase 
RT-qPCR Real time quantative polymerase chain reaction 
TBS Tris-buffered saline 
TIC Tumour initiating cells 
TSG Tumour suppressor gene 
UDP Uridine diphosphate 
  
 
 
a) 
b) 
 
Figure 1. The human breast structure and the terminal end bud. a) On the left there is an 
illustrative representation of the epithelial structure of the human mammary gland. On the 
right there is photomicrograph of a haematoxylin- and eosin-stained cross-section through a 
terminal ductal lobulo-alveolar structure. b) Represents a terminal end-bud. The three cell-
lines composing the gland are represented, as well as their localisation depending on their 
status of differentiation. The luminal cells or body cells create the alveoli by undergoing 
apoptosis. At the tip of the terminal end bud, are the stem cells that can undergo symmetric or 
asymmetric division.(Smalley & Ashworth, 2003) 
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II. Introduction 
 
A. Cancer stem cells and breast tissue 
 
1. Generalities on stem cells and breast tissue 
 
 As most epithelial tissues are under continual renewal, a stem cell component is 
necessary to ensure the plasticity of the tissue. Breast tissue, the focal point of this Master’s 
Thesis, is an example of an organ where the presence of such a stem cell component is 
particularly important due to continual morphological changes throughout the female’s life. 
To ensure the plasticity of these remodelling organs the body must coordinate and tightly 
regulate a hierarchy of at least three cell types, i.e. adult stem cells, amplifying cells, and post-
mitotic differentiating or differentiated cells. The stem cells reside in a specific environment 
known as the stem cell niche, where not only the contact with other cells but also with the 
microenvironment is primordial for a balanced regulation of the cellular pathways. The niche 
in which these undifferentiated cells reside controls self-renewal and asymmetric division, 
thus allowing the maintenance of tissues and the ongoing development of organs (Chaffer et 
al., 2011; Dontu et al., 2003; Mackenzie, 2005; Spillane & Henderson, 2007).  
 The mammary gland is a unique organ in the sense that its development occurs 
primarily after birth, but also because it undergoes continual changes throughout the various 
stages of the woman’s genital development. The epithelial cells composing the breast tissue 
respond to steroid hormones modifying the proliferative mechanisms to allow cyclical 
development of the organ (Charafe-Jauffret et al., 2008). To maintain the ongoing 
modifications to this particular tissue the stem cell component will ensure that the entire range 
of differentiated cells is present at all times by undergoing division and differentiation when a 
signal is received. One may surmise that a significant number of stem cells must be present in 
the breast tissue (Dontu et al., 2003; Ginestier et al., 2007a).  
 
2. Breast structure 
 
 The repertoire of differentiated cells composing the breast tissue is made up of three 
different cell lineages that create the lobulo-alveolar structure of the mammary gland, where 
each lineage has its own specific functions. The alveolar epithelial cells, also known as body 
cells, synthesize the proteins that compose the milk produced during lactation. Myoepithelial 
cells form the basal layer of both the alveoli and the ducts; they are responsible for the 
expulsion of milk. The ductal epithelial cells line the lumen of the ducts (Dontu et al., 2003; 
Ginestier et al., 2007a). Together these three cell lines compose what is also known as the 
terminal end bud. At the tip of these buds are cap cells, which are thought to be the ductal 
stem cells responsible for maintaining the entire cellular repertoire and ensuring growth of the 
gland in response to external signals (Fig. 1) (Smalley & Ashworth, 2003). 
 
3. Stem cells 
 
 Normal stem cells have both the ability to self renew and to undergo asymmetric 
division giving rise to a more differentiated progeny. The self-renewal of stem cells will 
provide a continuous pool of stem cells in the niche, from which the tissue can regenerate. 
Adult stem cells are multipotent, which means they have the ability to differentiate into 
various mature cells, but this capacity is usually limited to that of the specific tissue they 
occupy. When a stem cell undergoes asymmetric division the newly produced daughter cell 
can further divide and differentiate a certain number of times to eventually form the entire 
  
Figure 2. The immortal strand theory. After each asymmetric division a stem cell goes 
through, the template DNA strand (represented as the blue DNA strand) used for DNA 
replication prior to a division is always segregated to the stem cell. This phenomenon is 
specific to stem cells. The Renewed stem cell, will then go through the same process 
throughout its next asymmetric division. The immortal strand is passed down from one stem 
cell generation to the next. The daughter cell receives the newly synthesized DNA strand 
which may contain replicative associated errors that will later on be eliminated as these cells 
have a limited life span. This process aids in maintaining the integrity of the stem cell’s 
genome, which is ever so crucial for a cell that is endowed with the role of regenerating the 
entire population of cells composing a certain tissue. (Smalley & Ashworth, 2003) 
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variety of cells contained in the mature tissue (Smalley & Ashworth, 2003). Stem cells are 
resistant to apoptosis and anoikis (survival in non-adherent conditions), have the ability to 
migrate, and their long life span ensures the development of mature tissue throughout the 
organism’s entire lifetime (Spillane & Henderson, 2007). Although the stem cell can be 
active, such as undergoing asymmetric division and accomplishing self-renewal, another vital 
aspect of its life is the capacity to wait during long periods for a particular physiological sign 
(Smalley & Ashworth, 2003). 
 The regulation of these self-renewal pathways and the conservation of the stem cell 
pool are assured by transcription factors such as Notch, Oct4 and Nanog, as well as by 
signalling pathways transduced by Wnt/β-catenin, Hedgehog, TGF- β and PTEN amongst 
others (F. Zhang et al., 2011). Experimentally it is possible to provoke the dedifferentiation of 
committed cells by inducing the expression of Oct4, Nanog, Sox2, KLF4, c-Myc, and miR-
302. Oct4, Nanog, Sox2, KLF4, c-Myc are considered as the main stemness transcription 
factors. These particular proteins and micro RNAs are also known as induced pluripotent stem 
cell (iPSC) inducers (Mathieu et al., 2012). 
 
4. Maintaining the genome integrity in stem cells 
 
 As mentioned previously, stem cells can be found in specific niches. These niches 
have been shown to offer protection from oxidative damage to the genome, which is an 
important precaution in cells with a long life span that also have the crucial role of 
regenerating tissues. Oxidative damage by reactive oxygen species (ROS) can be limited by 
low oxygen concentrations, otherwise known as hypoxia, and also by the presence of 
hyaluronic acid (HA) (Keith & Simon, 2007). HA is thought to have anti-oxidative properties 
by directly scavenging hydroxyl radicals and by chelating the ions necessary for Fenton’s 
reactions, the reaction involved in producing the hydroxyl radicals (Darzynkiewicz & Balazs, 
2012). Hypoxia and HA are both components of the stem cell niche, thus providing an ideal 
residence for stem cells (Keith & Simon, 2007).  
 Another way stem cells might ensure the integrity of their genome throughout their 
long life span was first described by Cairns in 1975. The hypothesis is that the dividing stem 
cells segregate the newly synthesized DNA strand to the amplifying cell while the template 
DNA strand is preserved in the stem cell. This is also known as the immortal strand 
hypothesis, as the very same DNA strand is maintained and passed from the initial stem cell 
to the renewed stem cell from one generation to the next. The preservation of one DNA strand 
after stem cell renewal is an attractive theory as it means that the stem cell genome would not 
integrate any replication associated errors (Fig. 2). Today there is research that backs this 
hypothesis (Mackenzie, 2005; Smalley & Ashworth, 2003). 
 
5. Breast cancer and cancer stem cells 
 
The exact origin of tumours is still a widely disputed topic. It is possible that they are 
the product of epigenetic and genetic modifications of differentiated cells but lately an 
increasingly popular view has been that they could arise from modifications to the stem cells’ 
DNA. If these epigenetic or genetic alterations affect undifferentiated cells they could disturb 
the metabolic and the self-renewal pathways necessary for the homeostasis of the stem cells 
and consequently also that of the tissue they regenerate. Initial changes can give rise to pre-
malignant sub-clones, i.e. cells that have enhanced proliferative activity when compared to 
normal cells. The body’s natural defence mechanisms are able to keep these cells under 
control and inhibit the formation of malignant masses. These cells are considered as being 
pre-malignant. Some of the subclones may succumb to additional alterations or may receive 
 Somatic stem cell Cancer stem cell  
Self-renew, highly regulated Self-renew, poorly regulated  
Differentiate, produces mature tissue Differentiate, produces tumour 
Migrate to distant tissues  Metastasize to distant sites  
Long lifespan Long lifespan 
Resistant to apoptosis Resistant to apoptosis 
 
Table 1. Comparison of somatic and cancer (Spillane & Henderson, 2007) 
 
 
 
Figure 3. Normal adult stem cells compared to a cancer stem cell. Normal stem cells can 
self-renew to an extent that doesn’t seem to be limited. The stem cells can also undergo 
asymmetric division giving rise to a more differentiated cell, a committed progenitor. 
Division in stem cells occurs at a slow rate but is highly regulated. These stem cells are 
important for guarantying the homeostasis of the tissue. Oncogenic transformations can 
perturb the regulation of the division pathways, thus leading to cancer stem cells which divide 
in an uncontrollable manner, which can lead to tumour formations. (Keith & Simon, 2007) 
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signals from a perturbed microenvironment. That may be sufficient to push the pre-malignant 
stem cells into gaining malignant functions, giving the cells the ability to overcome the body’s 
control and develop into a malignant tumour mass (Bonnet & Dick, 1997; Grimshaw et al., 
2008; Spillane & Henderson, 2007; Valent et al., 2012). Such aberrant stem cells are now 
known as cancer stem cells (CSCs) (Fig. 3, 4 and Table 1). There are indications that CSCs 
reside in niches that provide abnormal information to the stem cell, which could be a possible 
reason for the dysregulation of stemness pathways. The hypothesis that altered stem cells and 
cells presenting a stem-like phenotype are at the origin of tumours has given rise to the 
concept of the CSCs, otherwise also known as tumour initiating cells (TICs), defined as cells 
that have the capacity to produce observable invasive tumours or leukaemia when 
transplanted into experimental animal models (Fazilaty et al., 2013; Li et al., 2012; Valent et 
al., 2012). These xenografted CSCs have the unique ability of recreating heterogeneous 
tumours, an outcome that does not occur when injecting animals with the differentiated 
cellular population (Wiestler, Mumberg, & Haendler, 2006).  
The aberrant communication between the cells and the niche may have numerous 
causes. Two of them are an aberrant response to hypoxia and an altered HA metabolism. They 
will be discussed later on. However, it is not yet known whether the miscommunication 
between the stem cell and its niche is due to the aberrant niche or whether the aberrant niche 
is a consequence of the apparition of CSCs (Gilbertson & Rich, 2007).  
Stochastically speaking it is more probable that a stem or progenitor cell, with a long 
life span, would acquire one or two mutations dysregulating its self-renewal pathways than 
this phenomenon occurring in differentiated cells, usually having a short life span. As stem 
cells and CSCs are multipotent, any dysregulation in their differentiation pathways could 
explain the heterogeneity of tumours since the differentiation processes stemming from these 
cells would become uncontrollable (Fig. 5) (Charafe-Jauffret et al., 2008; Ginestier et al., 
2007b; Spillane & Henderson, 2007).  
 Another possible reason for the generation of tumours could be a conversion of 
differentiated cells to cells presenting a stem-like phenotype, i.e. a dedifferentiation process 
(Chaffer et al., 2011; Dontu et al., 2003; Spillane & Henderson, 2007). Bearing in mind the 
immortal strand hypothesis, the conversion of a differentiated cell to a stem cell could be 
problematic if the genetic material passed onto the daughter cells had been subject to 
replication associated alterations. Due to the longevity of the stem cells the mutation in 
dedifferentiated cells would no longer be discarded as is the case in daughter cells. The 
maintenance of such mutations could give rise to a heterogeneous tumour after multiple 
divisions (Smalley & Ashworth, 2003). Which of the above CSC-linked theories best 
describes the reality of cancers is undecided yet. 
 CSCs have multiple characteristics that favour the development, the maintenance, and 
the recurrence of malignant tumours. One of these characteristics is the cell’s resistance to 
chemo- and radiotherapy due to a high expression of ABC transporters, a good capacity to 
repair DNA damage, and a resistance to apoptosis (Table 1). Another characteristic is the 
ability of CSCs to enter quiescence. This is a state of dormancy that enables cells to survive in 
unfavourable environments, as is the case during cancer treatment, whilst also remaining 
ready to reengage in the normal cell cycle when the environment is more favourable (Charafe-
Jauffret et al., 2008). Higher invasiveness can be associated with CSCs compared to the 
differentiated cell population. This could be due to an increased expression of proteins 
involved in infiltration such as vascular cell adhesion molecule (e.g. VCAM-1), integrins, 
chemokine receptors (e.g. CXCR4), and the HA receptor CD44 (Dontu et al., 2003; Mimeault 
& Batra, 2013a; Yu & Bian, 2009). When considering these characteristics favouring the 
development of a malignant tumour, it becomes obvious that therapies targeting these 
particular cells must be generated. However, due to conversion plasticity of CSCs to 
  
 
 
Figure 4. Model representing the evolution of cancer stem cells. Throughout the course of 
time a stem cell or progenitor cell may succumb to an epigenetic or genetic alteration. This 
alteration can provide progenitor cells with a stem-like phenotype. Proliferative abilities may 
be altered in a way that provides the cells with an advantage over normal cells. This 
Dysregulation of proliferative pathways may give rise to a persistent neoplastic clone. This 
initial clone, a pre-malignant stem (outlined in blue), can give rise to sublcones that are 
naturally brought under control by the immune system or the surrounding tissue, preventing 
the development of malignancy. Additional alterations, genetic, epigenetic or changes in the 
microenvironment can provide these pre-malignant cells with the ability to overcome this first 
phase of cancer evolution and consequently allowing a malignancy to develop. This 
corresponds to the second phase of the cancer development. It is at this point that the 
neoplastic stem cells can be considered as cancer stem cells (outlined in black), as they have 
acquired the ability to initiate cancer. The pre-malignant stem cells may continue to 
proliferate continually generating other pre-malignant cells that may acquire the additional 
modifications that could lead to them developing into a malignant neoplastic cell or cancer 
stem cell. (Valent et al., 2012)  
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differentiated cells and vice versa, the differentiated population must still be targeted 
throughout treatment (Chaffer et al., 2011).   
 
6. Cancer stem cell plasticity and heterogeneity 
 
The degree of heterogeneity of tumours could be explained by multiple genetic and 
epigenetic alterations occurring in differentiated cells or by the various external signals that 
can be delivered to cancer cells depending on where they reside in the tumour, as different 
locations bear different microenvironments. But in order to reach the extent of heterogeneity 
seen in many cancers, many separate differentiated cells must succumb to these mutations, a 
phenomenon that is statistically improbable. A simpler explanation could be the CSC 
hypothesis. The heterogeneity could arise in response to altered self-renewal, proliferation and 
differentiation processes in CSCs generating a tumour composed of cells presenting 
phenotypical and functional differences. According to that second theory the proportion of 
CSCs composing the mass would significantly influence the degree of heterogeneity in the 
tumour, as the more CSCs there are the more possibilities of differentiation emanate, 
especially when taking into account the influence of the various microenvironments that can 
be observed in tumours (Magee, Piskounova, & Morrison, 2012; Pece et al., 2010).  
The development of tumour heterogeneity is now often modelled as hierarchical, i.e. 
based on the CSC model, as opposed to the stochastical model, solely based on the 
differentiated population succumbing to a multitude of mutations. However, this hierarchical 
view is not entirely correct. There is evidently an array of functionally and phenotypically 
different cells composing the tumour mass. What is left out in this hierarchical model is the 
interconversional abilities of cells to change from one differentiated cell state to another. This 
can lead to problems while treating tumours as the targeted cells may be eradicated only to be 
replaced through the plastic abilities of CSCs or their daughter cells, leading to regrowth of 
the mass after the treatment. This means that even after targeting the initiators of tumours, the 
CSCs, the differentiated progeny could revert to a stem-like state if the adequate signals are 
received, thus enabling tumour regrowth after CSC targeting (Gupta, Chaffer, & Weinberg, 
2009; Heddleston et al., 2010; Pece et al., 2010). These issues bring to view just how crucial it 
is to target both differentiated and undifferentiated cells, and the necessity of developing 
treatments that will inhibit cellular plasticity.  
 
7. CSC isolation 
 
 Charafe-Jauffrets et al.’s article in 2008 reviews the many ways of isolating and 
culturing CSCs in vitro, each coming with their own advantages and disadvantages (Charafe-
Jauffret et al., 2008). CSCs can be isolated by the side population technique, which exploits 
the CSCs’ ability to exclude Hoechst 33342 or Rhodamine 123 dyes. Fluorescent-Activated 
Cell sorting (FACS) can also discriminate CSCs from differentiated cells as breast CSCs 
typically have high and low expressions of the surface receptor proteins CD44 and CD24, 
respectively (CD44
+
/CD24
-
). Another method of isolating CSC is by the ALDEFLUOR assay 
which recognizes enzymatic Aldehyde Dehydrogenase 1 (ALDH1) activity.  
 The technique used in our laboratory for isolating and enriching CSCs is based on 
their resistance to anoikis. This ability to evade programmed cell death in non-adherent 
conditions enables the stem/progenitor cell population to be cultured into floating spheres in 
vitro that are made up of stem cells and their progeny. Mammary epithelial CSCs can form 
mammospheres (MS) when cultured in non-adherent conditions. If the adherent culture is 
adequately isolated one CSC or one early progenitor cell can give rise to one MS as they are 
the only ones able to survive in these non-adherent conditions. Within these MSs are cells that 
  
Figure 5. The stochastic and hierarchical models for tumour generation and 
heterogeneity. In the stochastic model, multiple differentiated cells of the mammary 
epithelium succumb to mutations that supply the cells with increased proliferative activities. 
Due to this increased ability to proliferate tumour formation composed of various 
differentiated cells can develop. In the hierarchical model it is a single stem cell that 
succumbs to alterations that can provide it with increased proliferative and self-renewal 
abilities. There will not only be generation of various differentiated cells but there is also a 
generation of other CSCs (possessing these same proliferative and self-renewal abilities), 
which can explain the heterogeneity of tumours. (Ginestier et al., 2007) 
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maintain both the ability to self-renew and to undergo asymmetric division. These progenitor 
cells can further undergo differentiation and lead to the development of MSs containing a 
wide range of diverse cells, that can even recreate functional mammary gland structures 
(Dontu et al., 2003; Ponti et al., 2005a). The monoclonal origin and refutation of cellular 
aggregation as an origin for MS formation was shown by analyzing secondary sphere 
formation with fluorescently transfected cells (Dontu et al., 2003). Ponti et al. showed that 
when injecting MCF-7 cells from MSs into immunodeficient mice, only 10
3
 cells were 
sufficient to form tumours whereas a minimum of 10
6
 cells from total adherent population 
were necessary to form a tumour in these mice (Ponti et al., 2005b). Even though this in vitro 
model does not replace a physiological environment, MSs are ethically favourable, cheaper 
and easier to study than the transplantation of stem cells into immunodeficient mice, all whilst 
maintaining the heterogeneity of in vivo tumours (Valent et al., 2012).  
 
 
B. Hyaluronan, its metabolism and its implication in cancer 
 
1. Generalities on Hyaluronan 
 
 HA is a simple disaccharide (GlcNAcβ(14)GlcUAβ(13)) repeated 2500 to 25000 
times, forming a free glycosaminoglycan (GAG) polymer that plays a crucial role in the extra-
cellular matrix (ECM) of cells. HA is unique as it differs from other GAGs in the sense that it 
is non sulphated, isn’t attached to any core proteins, and its synthesis doesn’t involve the 
Golgi pathway but is instead synthesised at the plasma membrane (Stern, 2004). This GAG is 
negatively charged at a physiological pH and is considered as a high molecular weight 
polymer as it can reach up to 10
4
 kDa. The simplicity of this large polysaccharide does not 
merely reflect its intricate effects on the physiology and biology of vertebrates (Almond, 
2007; Bastow et al., 2008; Hubbar et al., 2012a). HA forms a network around cells, known as 
the glycocalyx, which increases the expanse of their extracellular domain, intervenes in cell-
cell interactions and can also act as a molecular sieve only allowing molecules of low 
molecular weight to pass (Almond, 2007; Bourguignon, Wong, Earle, & Chen, 2012a; Stern, 
2004, 2005). The negative charge present on pseudo-random coil of HA polymers means that 
within aqueous solutions it will occupy a large space thus procuring it with the roles of 
hydrating tissues and ensuring that all spaces between neighbouring cells are occupied. It is 
additionally responsible for cell motility by providing the necessary extracellular space and 
interacting with the cytoskeleton (Fig. 6) (Almond, 2007; Stern, 2003, 2004).  
Intriguingly HA appeared relatively late in the evolution of metazoan beings. HA is 
thought to play a role in the migration of foetal cells, allowing them to migrate more easily 
over significant distances, which does not occur in more primitive beings. It is also thought 
that HA may play a role in ensuring a physical separation between differentiated cells and 
undifferentiated cells. Thus a possible explanation for the late phylogenetic appearance of HA 
is that due to the fact that primitive organisms were mainly composed of multipotent cells, 
partitioning of the differentiated and undifferentiated cells was not necessary. The emergence 
of HA in later organisms could thus allow the separation of these different cells, allowing a 
more complex development (Stern, 2003).  
The catabolism of HA leads to the formation of fragments of different sizes. These 
fragments are generated by hyaluronidases (HYALs), the enzymes responsible for HA 
degradation, and have very different and even contradicting effects on cellular responses 
depending on their size. Angiogenesis and inhibition of apoptosis are two examples of 
physiological effects that HA fragments can have on cells. An abundant amount of the 
fragmented form of HA can be a sign of malignancy (Almond, 2007; Stern, 2003, 2004). 
  
 
Figure 6. Structure of Hylauronan, volume occupation by hyaluronic acid and 
hyaluronan synthesis.a) Representation of the disaccharide of glucoronic acid and N-
acetylglucosamin, which is the basis of hyaluronan. These disaccharides are repeated many 
times in hyaluronan. The polymer composed of these disaccharides has charged and 
hydrophobic faces due to the presence of glucoronic acid’s carboxyl groups on one side and 
hydrogen atoms on the other .b) The polymer occupies a large volume when it is present in a 
solution. The water molecules that get trapped within the polymer as well as the repulsion 
between carboxyl groups are responsible for the expansion of hyaluronan. Hyaluronan can 
execute internal pressure on physical structures providing the cells with routes that facilitate 
migration. c) Hyaluronan synthase enzymes are responsible for the synthesis of this polymer. 
At the inner membrane surface the monosaccharides are combined by a glycosyltransferase 
activity. Progressively the polymer is extruded to the outer plasma membrane where it can be 
retained by the enzyme or it can be released into the extracellular environment. X and Y 
represent putative regulatory proteins that aid the synthesis of hyaluronan. Adapted from 
(Hubbard, McNamara, Azumaya, Patel, & Zimmer, 2012; Toole, 2004) 
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Tumour development is one of the malignancies in which HA metabolism is known to be 
implicated, and these masses often present a high quantity of the fragmented HA form. Before 
reviewing how HA and its metabolism are involved in tumourigenesis it is important to go 
over the normal synthesis and degradation of HA, in order to understand the underlying 
problems that can drive tumour formation and malignant development. 
  
2. Hyaluronan metabolism 
a) Synthesis 
 
In alternation, at the inner plasma membrane surface, one UDP-N-acetyl-D-
glucosamine and one UDP-glucoronic-acid polymerise after losing their nucleoside 
diphosphate. This process is catalyzed by enzymes known as HA synthases, which exist in 
three isoforms (HAS1, HAS2 and HAS3) (Almond, 2007; Bastow et al., 2008; Stern, 2005). 
HAS proteins are integral membrane proteins embedded in the inner plasma membrane. 
During the elongation of HA the chain of repeated disaccharides is gradually extruded, but not 
secreted, towards the extracellular environment of the cell (Fig. 6) (Hubbard, McNamara, 
Azumaya, Patel, & Zimmer, 2012b; Rilla et al., 2013; Williams, Motiani, Giridhar, & Kasper, 
2013).  
HAS enzymes are present only in a very low concentration which leads researchers to 
believe that the main regulation of HA levels is done at the catabolic level (Stern, 2004). Not 
only is it important to regulate the concentration of HA in normal unaffected tissue but also 
during physical stress (tumourigenesis, septicaemia, wounds, burns, blood loss, etc.) as HA 
intervenes in the healing processes of such lesions. Rapid increases in HA levels occur at 
affected sites and must thereafter be decreased with the help of HYALs (Stern, 2008a).  
b) Degradation 
 
 The daily turnover of HA and the degradation of HA after the wound healing process 
are both carried out by HYALs. They can fragment HA into polymers of different sizes 
ranging from 20 kDa fragments to tetrasaccharides. With the help of this hyaluronidase 
activity, the daily turnover rate of HA in vertebrates is estimated to be of 33 %, which is 
considered to be particularly high. The turnover is even greater in malignant tissues such as 
tumours where one can find a high concentration of fragmented HA (Stern, 2008a). In 
mammals the HYALs responsible for the degradation of HA are endo-β-acetyl-
hexoaminidases; they fragment HA by hydrolysis. There are six hyaluronidase-like genes 
(HYAL1, HYAL2, HYAL3, HYAL4, PHYAL1 and SPAM1) present in the human genome, but it 
is HYAL1 and HYAL2 that are responsible for the majority of HA catabolism (Bastow et al., 
2008; Stern, 2004). Both of these HYALs are acid active, and both are present in two 
isoforms. HYAL2 has a glycosylphosphatidylinositol (GPI) link that anchors it to the plasma 
membrane. HYAL1 has a molecular weight of 57 kDa or 45 kDa depending on whether it has 
been processed by an endoprotease reaction (Stern, 2004, 2005). It can be found in the 
extracellular space as well as within the cells. There is some conflicting information on the 
subcellular localisation of HYAL1, although there are indications leading researchers to 
believe that it may be located and effectuate its function in early lysosomes (Andre et al., 
2011; Gasingirwa et al., 2010; Stern, 2003, 2004, 2005). Stern even suggests the possible 
existence of an organelle dedicated to the catabolism of HA, first described by Mian in 1986, 
known as the hyaluronasome (Mian, 1986; Stern, 2003).  
HYAL2 fragments HA of high-molecular mass into polymers of approximately 20 
kDa. HYAL1 on the other hand doesn’t have size specific activity and can consequently 
  
 
Figure 7. Hyaluronan degradation. This is the widely accepted cascade scheme for 
hyaluronan catabolism. It starts with the high molecular weight polymer which is internalised 
at microdomains known as caveola and degraded by HYAL-2 into fragments of 50 
disaccharides. Next HA is fragmented into smaller fragments by HYAL-1, N-
acetylglucosaminidases and glucorinidases. (Stern, 2004) 
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degrade HA of all sizes into smaller fragments such as tetrasaccharides and disaccharides 
(Stern, 2004). The catabolism of HA initiates at specific sites on the cell membrane known as 
lipid rafts. At these microdomains HA is taken up into the cells after recognition by CD44. 
CD44, a transmembrane cell surface receptor and also an adhesion protein, can interact with 
HYAL2 during the catabolism of HA. At these particular microdomains a HA-CD44-HYAL2 
complex will initiate the cleavage of HA into smaller fragments. As HYAL2 is acid-active, a 
low pH is ensured by a Na
+
/H
+
 exchanger. After internalisation the fragments will follow the 
endocytic membrane transport pathway by first being delivered to endosomes and then 
probably to lysosomes. Supposedly it is within the lysosomes that HYAL1 will further 
degrade the HA fragments into limit fragments with the help of three other enzymes, notably 
β-exoglycosidases, β-glucuronidases and β-N-acetylglucosaminidases (Fig. 7) (Bastow et al., 
2008; Ponta, Sherman, & Herrlich, 2003; Stern, 2004, 2008a; Williams et al., 2013). 
 Another means of HA degradation is by ROS. High molecular weight (HMW) HA has 
ROS-scavenging abilities by which it directly interacts with the oxidants, which leads to the 
breakdown of the polymer of HA (Darzynkiewicz & Balazs, 2012). 
 When an increase in HA is necessary, as is the case during an important physiological 
stress, HYAL inhibitors are released in response, e.g. to IL-1, which will rapidly inhibit the 
body from degrading HA. In normal healthy tissues the presence of HYAL inhibitors is very 
important as they help maintain the extracellular matrix (ECM) by stopping HA degradation 
when it is not necessary (Stern, 2004, 2008a). 
  
3. The association of hyaluronan with proteins 
  
 The binding of HA to CD44 doesn’t solely play a role in the uptake of the polymer for 
metabolism, it is also highly involved in signal transduction which is involved in cellular 
differentiation, proliferation, survival and motility. RHAMM is another receptor capable of 
transducing signals involved in cellular processes such as proliferation, survival and motility 
after having bound HA. The involvement of hyaladherins, in particular CD44, is relevant to 
this particular study as the mentioned cellular processes are implicated in stemness and 
tumourigenesis (Bourguignon et al., 2008; Bourguignon et al., 2012a; Bourguignon et al., 
2012b; Hiraga, Ito, & Nakamura, 2013; Toole, 2004). 
 CD44 is made up of a single chain which presents an ecto-, a transmembrane-, and a 
cytoplasmic domain. Multiple isoforms of CD44, one standard form and a number of 
alternative forms, exist as this adhesion glycoprotein can undergo various combinations of 
splicing during the transcription of its gene (Olsson et al., 2011; Thorne, Legg, & Isacke, 
2004; Toole, 2004). HA binds to the extracellular domain which can activate the receptor. In 
response to HA the cytoplasmic domain can interact with an array of proteins such as tyrosine 
kinases, phosphatidylinositol 3-kinase (PI3K), PKC, RAS, ERBB and Nanog. It is via these 
signalling pathways that HA bound to CD44 is involved in tumour development, maintenance 
and metastasis (Bourguignon et al., 2008; Toole, 2004).  
 
4. Biological functions of hyaluronan 
 
 Depending on the size and molecular weight of the HA fragments different 
physiological effects can be induced on the organism. As previously mentioned HMW HA 
has a role of filling the voids between cells and for hydrating tissues. This HMW polymer also 
has anti-angiogenic, anti-inflammatory and immunosuppressive effects on the organism. The 
intermediate sized HA fragments, weighing between 20 kDa and 6 kDa, promote 
inflammation by stimulating the production of pro-inflammatory cytokines, and enhancing 
angiogenesis, the immune response and the endothelial recognition of injury. The 
 Table 2. Size dependent physiological effects of HA on the organism (Stern, 2004) 
HA fragment Physiological effect of HA fragment 
>100
  
kDa (extracellular high-molecular 
weight polymer) 
Space filling 
Hydrating 
Anti-angiogenic 
Anti-inflammatory 
 Immunosuppressive 
20 kDa (intermediate or low molecular 
weight fragment) 
Angiogenic 
Immunostimulatory 
Inflammatory 
 Endothelial injury recognition 
 MMP expression 
Small oligomers: tetrasaccharides 
Induction of heat-shock proteins 
Anti-apoptotic 
 Anchorage independent growth 
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transcription of matrix metalloproteases (MMPs) can also be induced by these intermediate 
size fragments of HA. The smaller HA fragments known as oligosaccharides having a chain 
of 3 to 10 disaccharides can stimulate anchorage independent growth of tumour cells. The 
expression of heat-shock proteins can be activated by tetrasaccharides, which can also have 
antiapoptotic effects. A summary of these physiological effects is available in Table 2. It’s 
quite astonishing to see how some of these effects are completely contradicting. This just 
shows the complexity of HA and indicates that its regulation must be closely monitored in 
order to maintain not only cellular but also organismal homeostasis. Defects in the 
metabolism of HA have been seen to lead to malignancies as is the case in tumour 
development (Stern, 2003, 2004). 
 
5. Implication of hyaluronan in cancer 
 
 The tumour cell’s inherently instable genome means that it frequently succumbs to 
change, which can make it difficult to truly understand the underlying mechanisms that lead 
to the development of such malignancies in the first place (Stern, 2005, 2008a). It has in fact 
been shown that HA and its metabolic partners such as HYALs, HYAL inhibitors and CD44 
play an important role in tumour progression (Hiraga et al., 2013; Stern, 2004, 2008a; 
Sugahara et al., 2003). 
 Malignant tumours present higher concentrations of HA than normal tissues and have 
a considerate influence on the sheer mass of the tumour (Stern, 2005, 2008b). This can either 
be due to a high production of HA by the tumour cells themselves or to the synthesis of HA 
by the surrounding cells making up the microenvironment. The area surrounding the tumour 
known as the peritumour stroma has certain similarities to embryonic stroma. How this 
“embryonic environment” develops is not yet clear, but it is speculated that the tumour’s 
paracrine signalling intervenes in the process (Stern, 2005). Abnormal HA metabolism is one 
of many components of the peritumour stroma which promotes tumour cell proliferation, 
invasion and metastasis (Hiraga et al., 2013; Stern, 2005). In ovarian and breast cancer (BC) 
there is an inverse relationship between the levels of HA in the tumour stroma and the rate of 
patient survival. It has also become evident that the visualisation of the areas presenting an 
increased amount of HA by sonography can give a clearer idea on the shape and size of the 
tumour than a mammography (Toole, 2004). 
 Overexpression of HAS proteins can be observed in various cancers, such as 
fibrosarcoma, prostate carcinoma and mammary carcinoma. A recent paper notes that HAS2 
is overexpressed in breast CSCs; this will be detailed in the point addressing the impact of HA 
on normal stem cells and CSCs. In metastatic colon cancer there is an overexpression of 
HAS3 and an increased amount of HA. The up-regulation of this protein facilitates anchorage 
independent growth and promotes growth and progression of colon carcinoma (Bullard et al., 
2003; Okuda et al., 2012). 
 HYAL1 and HYAL2 are both contributors to cancer progression in their own way. 
HYAL1 is considered to be the product of a tumour suppressor gene (TSG). Cancers have the 
ability to eradicate any activity that is harmful to the tumour itself (Stern, 2004). In many 
cancers such as breast cancer the gene can either be deleted or silenced epigenetically through 
a hypermethylation of CpG islands or through a silencing at the RNA level (Stern, 2005). 
Inhibition of HYAL1 entails an accumulation of oligosaccharides which promote malignant 
transformation and progression by the stimulation of mechanisms such as angiogenesis (Stern, 
2008a). HYAL2 is considered to be an oncogen as well as a TSG. In some instances its 
overexpression is accompanied by an acceleration of tumour progression. By increasing the 
rate of apoptosis the gene coding for this enzyme can also be considered as a TSG (Stern, 
2004, 2005).  
 Figure 8. The regulation of signalling cascades by the CD44-hyaluronan interaction. The 
hyaluronan synthesised by hyaluronan synthases is extruded to the plasma membrane. There 
the polymer can interact with proteoglycans and very importantly CD44, the main HA 
receptor. During HA’s interaction with CD44 there is induction and/or stabilisation of its 
signalling domains located in the plasma membrane. These domains hold receptor tyrosine 
kinases such as ErbB2 and EGFR and non-receptor kinases such as the Src family. These 
enzymes are drivers of oncogenic pathways via MAP kinase and PI3 kinase/Akt cell that 
stimulate proliferation and survival pathways as well as the expression of transporters that 
provide the cells with drug resistance properties and contribute to the acquisition of malignant 
properties. Via the interaction with adaptor proteins these signalling pathways can be 
regulated. This schematic view of the effects of the interaction between CD44 and HA 
elucidate how autonomous activities can be induced and maintained in tumour cells  (Toole, 
2009) 
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 HYAL inhibitors are important for maintaining a functional and healthy ECM, as they 
can regulate the rate of metabolism of HA. It has become apparent that cancer patients have 
different classes of HYAL inhibitors compared to healthy patients. In these patients the 
presence of constitutively active forms of inhibitors are common. By inhibiting HYAL1 an 
accumulation of intermediate-sized HA fragments can stimulate angiogenesis which is a 
known contributor to cancer progression (Stern, 2005, 2008a).  
 Intermediate sized fragments of HA can also induce the cleavage of CD44 from the 
cell surface. Cell growth can thus become adhesion independent as the cleavage of CD44 by 
metalloproteases can mediate motility and invasion of cancer cells. Elevated levels of CD44 
cleavage have been seen in colon, ovarian, non-small cell lung, and breast cancers (Sugahara 
et al., 2003; Thorne et al., 2004).  
 As previously mentioned the interaction between HA and surface receptors such as 
CD44 has an impact on cell survival, proliferation and motility. Cellular responses engaging 
PI3K, protein kinase C (PKC), RAS and other such enzymes known to be highly implicated 
in tumour development are activated. Any disruptions in these pathways could be obvious 
contributors to tumour development and progression (Fig. 8) (Toole, 2004).  
 The elevated amounts of HA present in cancerous tissue can also protect the tumour 
cells from the immune system due to the formation of a protective barrier (Sugahara et al., 
2003). 
 
6. Implication of hyaluronan in stem cells 
  
 An indicator that HA is vital for stem cells is the fact these cells have a high 
expression of the main HA receptor, CD44. This glycoprotein when used as a stem cell 
marker can discriminate the undifferentiated population from the differentiated one. Through 
this receptor many different signals can be transduced that are involved in processes such as 
the alteration or maintenance of the cell’s differentiation status, inducing migration but also in 
processes linked to tumourigenesis. 
 Certain transcription factors associated with stemness can be activated by HA. This is 
the case for Nanog, Oct4 and Sox2 which are all stem cell markers. When HA binds to CD44 
it can interact and activate PKC which in turn phosphorylates Nanog. Under this activated 
state nuclear translocation of Nanog is possible, thus allowing it to induce the transcription of 
genes that are involved in reducing apoptosis and chemosensitivity, which are some of the 
characteristics of CSCs. In another model HA binds to CD44v3 and induces the production of 
miR-302 through the CD44-HA induced nuclear translocation of a transcription factor 
complex made up of Oct4, Sox2 and Nanog. miR-302 induces the expression of genes 
involved in stemness (Fig. 9) (Bourguignon et al., 2008). 
 HA’s ability to create an embryonic-like environment is of considerable importance 
for stem cells as it will allow them to maintain their genomic integrity. For CSCs this is even 
more of an advantage as it means that the cells could be protected from the different 
treatments aiming to damage the DNA in order to rid the patient of the aberrant cells forming 
the tumour mass (Charafe-Jauffret et al., 2008; Darzynkiewicz & Balazs, 2012; Keith & 
Simon, 2007; Stern, 2005). This protective environment means additionally that any 
mutations that may have already been acquired, by the CSC or by daughter cells reverting 
back to a stem-like phenotype, can be maintained and, through asymmetric cell divisions 
these mutations can be propagated (Charafe-Jauffret et al., 2008; Spillane & Henderson, 
2007).  
 It has been reported that the cleavage of the ectodomain of CD44 is an important step 
for cell migration in a HA based ECM. Shedding this glycoprotein at the rear of the cell is 
linked to detachment from the matrix. The front of the cell, the side leading the migration, 
 Figure 9. A model for the regulation of cancer stem cell functions via CD44-HA 
mediated Oct4-Sox2-Nanog signalling induced miR-302 production. In step 1, HA binds 
to CD44 which interacts with the Oct4-Sox2-Nanog complex (step 2). In step 3, the 
transcription factor complex can translocate to the nucleus, and bind to the promoter of the 
miR-302 cluster (step 4). The binding of this complex induces the transcription of miR-302 
(step 5) and the production of mature miR-302 (step 6). miR-302 downregulates protein 
involved in epigenetic regulation (step 7 and 8) and up-regulates survival proteins (step 8) 
which increases selfrenewal, clonal formation and contributes to chemoresistance. Adapted 
from (Bourguignon, Wong, Earle, & Chen, 2012) 
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will have a high expression of CD44, allowing the cell to latch on to the ECM. Thus this 
repetition of attaching and detaching accompanied by a cytoskeletal rearrangement at both 
poles of the cell will allow the cell to move forward (Nagano & Saya, 2004).  
 A recent publication has revealed that a high expression of HAS2 is vital in breast 
CSCs for bone metastasis (Okuda et al., 2012). The high expression of this enzyme appears to 
be linked to better adhesion to endothelial cells and increased ability to transmigrate through 
an endothelial monolayer. The increased production of HA by HAS2 increases the CSC’s 
interaction with stromal cells in the bone, thus contributing to increased proliferation. The 
authors point out the fact that HAS2 is an essential factor in providing CSC with the ability to 
metastasize. Their findings show that metastatic CSCs have an elevated expression of HAS2 
and that HA is an important factor in the interaction with surrounding cells such as tumour 
associated macrophages. This interaction can stimulate the secretion of growth factors that in 
turn stimulate the growth of CSC (Okuda et al., 2012).  
 
C. Hypoxia 
 
1. Generalities on hypoxia 
 
 Once a tumour has grown to a certain size the oxygen delivery to the cells composing 
the mass is no longer adequate, leading to hypoxic zones. Hypoxia is defined as any oxygen 
tension too low to allow normal cells and organs to function in their typical way. These low 
concentrations of oxygen don’t provide a favourable microenvironment for most cells, 
entailing the appearance of necrotic zones. These zones can be observed in tissue areas that 
are situated approximately 70 µm -180 µm away from a blood vessel. Although hypoxia is 
considered to be toxic for most cells, some cells, such as stem cells and cancer cells have or 
can acquire mechanisms to survive and proliferate in these conditions. This low concentration 
of oxygen is thought to favour and allow the maintenance of a stem cell phenotype as well as 
contribute to altered HA metabolism via the intermediate of compounds such as Hypoxia-
inducible factors (HIFs) and lactate (Keith & Simon, 2007; Y. Kim, Lin, Zelterman, & Yun, 
2009; Krishnamachary et al., 2012; Stern, 2008a; Vaupel, Höckel, & Mayer, 2007) 
 
2. Causes of hypoxia and cellular responses 
 
 Hypoxia is a localised condition that occurs in solid tumours due to decreased oxygen 
availability. The low O2 partial pressure is a result of poor vascularisation and over-
consumption of oxygen due to the high proliferative activity of the tumour mass. The hypoxia 
can also be caused by anaemia induced by the therapies aiming to treat cancer (Keith & 
Simon, 2007; Vaupel et al., 2007). The key response elements inducing the adaptive changes 
in hypoxic conditions are HIFs. One of the most studied responses that is induced through this 
pathway is the VEGF activated neoangiogenesis (Harris, 2002). These mediators of the 
response to low oxygen levels are activated when physically the cells are localised too far 
away from an oxygen source. It’s not only the increased distance between the cells and blood 
vessels that leads to hypoxia but also the fact that the rapidly induced angiogenesis produces 
poor neovasculature. These newly synthesized blood vessels are leaky and unorganised (Liao 
& Johnson, 2007). Hypoxia is considered to be toxic for differentiated normal and cancer 
cells and usually induces cell death by activating p53 or up-regulating NIX and NIP3 
(mediators of cytochrome c independent cell death). But cancer cells are able to adapt to this 
particular form of stress. Cancer cells have the ability to not only survive in this oxygen 
deprived microenvironment but also to take advantage of it. Increased malignancy, poor 
 Figure 10. A summary of some of the genes activated by HIF-1α and HIF-2α. The genes 
activated by these HIFs are involved in processes such as: dedifferentiation, EMT, 
proliferation, survival, angiogenesis, invasion, metastasis, metabolism and O2 transport. 
(Cuvillier et al., 2013) 
 
Figure 11. Regulation of cell-death pathways by hypoxia. HIF-1α activates the 
transcription of many pro-apoptotic genes, induces cytochrome c independent cell death and 
activates p53 an inducer of apoptosis. HIF-1α also induces the transcription of a pro-apoptotic 
protein IGF-binding protein 3 (IGFBP-3). IGFBP-3 inhibits IGF-1R signalling. This 
signalling first activates a cascade which inhibits BAD, a pro-apoptotic protein. So by 
inhibiting IGF-1R this inhibition is lifted and apoptosis can be induced. (Harris, 2002) 
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patient outcome and resistance to chemo- and radiotherapy are accompanied by tumour 
hypoxia (Harris, 2002; Keith, Johnson, & Simon, 2012).  
 HIFs are heterodimeric complexes that comprise an O2 regulated bHLH-PAS α-
subunit and an aryl hydrocarbon nuclear translocator (ARNT) β-subunit (Al Okail, 2010; 
Harris, 2002; Keith et al., 2012). The α-subunit exists in 3 isoforms, HIF-1α, HIF-2α and HIF-
3α. Information on the effects, the localisation and the induction of HIF-3α are scarce. HIF-
2’s localisation is thought to be developmental stage- and tissue specific whereas HIF-1 is 
ubiquitously expressed in all cells (Chiavarina et al., 2012). In the presence of O2 the α-
subunits of HIF undergo HIF-specific prolyl-hydroxylase (PHD) modification which leads to 
rapid proteasomal degradation. This degradation is mediated by the Von Lippel Lindau 
(pVHL) tumour suppressor protein which can only recognize HIF in its hydroxylated state. 
Redox-dependent proteolytic stabilisation of the α-subunit prevents proteasomal degradation 
and enables translocation to the nucleus where it can interact with the oxygen independent 
HIF β-subunit (Chilov et al., 1999). Once in the nucleus the α- and β-subunits form a complex 
that can bind to hypoxia-response elements (HRE) and induce the transcription of multiple 
genes. The two highly homologous isoforms HIF-1α and HIF-2α are activated by different 
oxygen tensions and share many but not all HRE binding sites. This means that the two 
different HIFs activate some common genes while other gene inductions are isoform-specific 
(Keith & Simon, 2007; Li et al., 2009). Severe hypoxia is considered as an oxygen level of 1 
% or below, and moderate hypoxia ranges from above 1 % to 5 % oxygen. Severe hypoxia is 
necessary to activate HIF-1α whereas moderate hypoxia is sufficient to stabilise HIF-2α and 
allow its nuclear translocation (Li et al., 2009). The genes activated are involved in oxygen 
transport, glucose uptake, stemness, stress response pathways, cell adhesion, migration, and 
immortalisation (Fig. 10). One of the HIF-1α induced cellular responses is the induction of 
apoptosis which decreases the proliferation rate of the tumour by stimulating pro-apoptotic 
proteins such as NIX, NIP3 and p53 (Fig. 11) (Cuvillier et al., 2013; Harris, 2002).  
 
3. Taking advantage of hypoxia 
 
 The ability of cancer cells to adapt to a multitude of environments and to bypass 
situations in which they are receiving signals to undergo apoptosis is extraordinary (Fig. 12). 
They can manage to escape treatments causing damage to their DNA and to survive in 
environments deprived of nutrients and oxygen (Harris, 2002).  
Many cancer cells overcome hypoxia-induced apoptosis by overexpressing anti-
apoptotic genes such as IAP2 or by modulating mediators of the apoptotic pathway. Hypoxia 
can increase the activity of PI3K which intervenes in pathways that stimulate proliferation and 
inhibit apoptosis. HIF-1α can increase the expression of RAS, a potent oncoprotein and 
GTPase responsible for the activation of proteins involved in growth, differentiation and 
survival. Hypoxia participates in immortalising cancer cells. This is possible through the 
enhanced activity of telomerase enzymes enabling the cell to overcome its normally restricted 
replicative capacity. Many modifications to the DNA of oncogenic cells are not only 
provoked but also maintained by hypoxia. DNA repair in many of these transformed cells is 
impaired when they are cultured in low pH and low oxygen environments. Gene amplification 
is induced and fragile sites on chromosomes are more likely to succumb to DNA breaks. This 
increases genetic instability and supports malignant progression (Harris, 2002). 
 One of the metabolic adaptations enabling survival of cancer cells in a hypoxic 
environment is the switch from aerobic to anaerobic metabolism. This switch seems to be 
under the regulation of HIF-1α (Chiavarina et al., 2012). The expression of genes coding for 
metabolic enzymes such as GLUT1, ensuring glucose uptake, and lactate dehydrogenase 
(LDH), favouring anaerobic metabolism, are activated after HIF-1α stabilisation and nuclear 
 Figure 12. Cellular adaptations leading to cancer progression. HIFs can activate many 
various pathways that can lead to cancer progression and increased malignancy. This is 
achieved by the activation of stemness genes, by altering metabolism, inducing EMT, 
increasing angiogenesis and favouring survival mechanisms. (Mimeault & Batra, 2013) 
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translocation (Harris, 2002). Via glutaminolysis glutamine is used as a favoured source of 
energy in cancer cells. This amino acid is used either to regenerate pyruvate via the malic 
enzyme or, by entering the Krebs cycle, to replenish the intermediates that are necessary to 
generate lipids, nucleotides and other amino acids required for cancerous cells with high 
proliferative activity (Hirschhaeuser, Sattler, & Mueller-Klieser, 2011; Upadhyay et al., 
2013). Although endowed with a high glucose uptake cancer cells seem to evade the oxygen 
dependent tricarboxylic acid cycle by favouring the production of lactate from pyruvate via 
LDH. Directing glucose metabolism toward anaerobic catabolism decreases the overall pH of 
tumours. For tumours a decreased pH is actually favourable as it stimulates growth and 
invasion of neighbouring tissues and protects the cancer cells from the immune system. By 
only undergoing glycolysis and evading the mitochondria completely the cell generates 2 
molecules of ATP for each molecule of glucose compared to 36 molecules of ATP produced 
in the Krebs cycle. This method of metabolism seems to be less efficient but comes with the 
advantage of generating metabolic intermediates that can be used to synthesize nucleotides, 
amino acids and lipids. This process occurs in cancer cells as well as in normal proliferating 
and migrating cells. It can also take place in normoxic cancer cells where it is known as the 
Warburg effect (Harris, 2002; Upadhyay et al., 2013; Vander Heiden et al., 2009). 
 The effects of low oxygen can outlast the duration of hypoxia, or even become 
permanent. This is due to the epigenetic changes caused by hypoxia (Harrison et al., 2012; 
Upadhyay et al., 2013) 
  
4. The influence of hypoxia on hyaluronan metabolism 
 
 Hypoxia can indirectly regulate HA metabolism. For instance, many genes involved in 
HA metabolism have lactate-sensitive response elements in their promoters (Stern, 2008a). 
This is the case for CD44, HYAL1, and HYAL2, whose transcriptions are all activated by the 
by-product of the altered metabolism. Increased expression of CD44 in cancer cells or in the 
cells composing the tumour microenvironment in turn promotes cancer cell growth and 
motility (Formby & Stern, 2003; Hirschhaeuser et al., 2011; Stern, 2008a).  
 Recently it has been discovered that HIF-1α directly induces the expression of CD44. 
Not only the standard isoform of CD44 (CD44s) but also two variants, CD44v6 and CD44v8, 
are up-regulated in response to hypoxia. The alternate splice forms of CD44 are both 
associated with poor patient outcome, whereas CD44s is considered as a sign of good clinical 
outcome. CD44’s involvement in cellular differentiation creates an indirect tie between 
hypoxia, HA metabolism and stem cells (Krishnamachary et al., 2012). 
 
5. Hypoxia and cancer stem cells 
 
 CSCs seem to have a primordial role in tumour progression (Mimeault & Batra, 
2013b). This suggests that they can reside in the hypoxic environments that compose the 
natural stem cell niche but also arise in solid tumours (Keith et al., 2012; Louie et al., 2010). 
A study conducted by Mathieu et al. shows that there is an expression overlap of the genes 
involved in stemness when comparing human embryonic stem cells and cancer cells cultured 
in hypoxia (Mathieu et al., 2012). The hypoxic environment seems to be a crucial factor for 
all types of stem cells (embryonic, adult, and CSCs) as it maintains pluripotent potential, 
inhibits differentiation, and maintains the integrity of the genome (Keith & Simon, 2007; Li et 
al., 2009). HIFs can modify transcription factor expressions and signalling pathways involved 
in differentiation processes, inducing the maintenance or acquirement of a stem cell 
phenotype. This is possible by activating the expression of iPSC inducers. 
 Figure 13. HIF isoform specific stemness associated gene activations. In some hypoxic 
tumour cells HIF stabilisation and nuclear translocation will induce the transcription of genes 
involved in the stemness process, such as Notch, ABC-transporter, Oct4, c-Myc and maybe 
some of the other iPSC inducers too (KLF4, Sox2). The activation of these genes can bestow 
the cells with stem cell properties, such as self renewal (indicated with a green arrow) or 
induce dedifferentiation. These cells could have an increased potential to replicate which can 
lead to the formation of tumours if not brought under control. (Keith & Simon, 2007) 
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Both HIF-1α and HIF-2α are involved in activating genes necessary for stemness such 
as those coding for Notch or ABC transporters (which bestow the stem cells with their 
capacity to expulse drugs) but it seems that HIF-2α may have the predominant influence on 
limiting differentiation. HIF-2α directly activates two of the four main stemness transcription 
factors, Oct4 and c-Myc, but not the remaining two factors, KLF4 and Sox2. To this day HIF-
2α is still poorly understood and could possibly offer more insight into cancer initiation 
through CSCs (Fig. 13) (Keith & Simon, 2007). HIF-1α is thought to be primarily involved in 
inducing neo-angiogenesis and directing the CSCs to express the enzymes necessary for 
anaerobic metabolism (Keith et al., 2012). 
 ALDH, a CSC biomarker, is highly up-regulated in many BCs and can be linked to 
poor clinical outcome. Genomic analyses indicate that this enzyme can be highly expressed 
during oxidative stress, which can occur after re-oxygenation of a hypoxic environment. 
Proliferation and differentiation of mesenchymal stem cells has been associated to a high 
ALDH activity in a hypoxic environment. This indicates that there is a correlation between 
hypoxia, ALDH and CSC. Further studies in this domain showed that ALDH activity can 
indeed activate HIF-2α (Kim et al., 2012). 
 Hypoxia is thought to induce CSCs to undergo epithelial-mesenchymal transitions 
(EMT), a process that is critical for metastatic activity. Cancer cells that have undergone EMT 
can be characterised as having increased migratory and invasive abilities. In invasive breast 
tumours the molecular process leading to this change in phenotype is thought to be caused by 
a hypoxia induced up-regulation of Jagged2, which in turn activates the Notch pathway 
involved in stemness and EMT (Mimeault & Batra, 2013a, 2013b). CSCs with an EMT 
phenotype in hypoxic conditions are able to maintain this status even after re-oxygenation, 
thus maintaining their ability to migrate. Differentiated cells are also able to undergo EMT but 
after re-oxygenation these cells revert to their epithelial status via mesenchymal-epithelial 
transition. Cells cultured in non-adherent conditions can be enriched in CD44+/CD24- cells 
after multiple re-oxygenation cycles. Within these cell cultures hypoxia can activate the 
Wnt/β-catenin pathway as well as the PI3K/Akt cascades. These studies have revealed that 
this activation confers CSCs with higher MS-forming and clonogenic abilities (Mimeault & 
Batra, 2013a, 2013b). 
 The hypoxic environment can drive cancer progression by interfering with cellular 
communication. The hypoxic zones observed in breast tumours but also naturally found in the 
bone can promote bone metastasis by modifying cytokines (SDF-1) and growth factors (Bone 
Morphogenic Protein (BMP) and TGF-β1) released by stromal cells and BC cells. These 
molecules can influence self-renewal, survival, dormancy, and the ability of breast CSC to 
generate osteolytic bone metastasis (Mimeault & Batra, 2013a, 2013b). 
 Not all CSCs will respond to hypoxia in the same way; that will depend on certain 
protein expressions such as those of ER-α and E-cadherin (Chu et al., 2013; Harrison et al., 
2012). E-cadherin is a protein involved in cell-cell interactions, and its expression is lost 
during EMT. This change of phenotype enables migratory events necessary for metastasis in 
hypoxic conditions, but only in CSCs presenting low E-cadherin and high vimentin 
expressions (Salnikov et al., 2012). CSCs issued from ER-α positive cell lines have higher 
MS-forming abilities than those from ER-α negative cell lines (Harrison et al., 2012). It is not 
yet entirely determined what mechanisms are involved in increasing the fraction of 
undifferentiated cells. There are indications that self-renewal pathways are altered and that a 
certain proportion of dedifferentiation occurs in ER-α positive cells, leading to an increased 
proportion of CSCs. In the ER-α negative cell lines it is thought that hypoxia modifies 
proliferation and differentiation, causing a reduced number of CSCs (Harrison et al., 2012). 
This is merely a slight indication of how complex the effects of hypoxia on cancer 
progression are. A more in-depth comprehension of the underlying molecular mechanisms is 
  
Figure 14. Contribution of hypoxia-inducible factors (HIF) to cancer progression. In 
oxidative conditions, as is the case in normoxia, the HIF-α subunits undergo hydroxylation 
via prolyl-hydroxylase (PHD). In this hydroxylated state the α-subunit can bind to Von Lippel 
Lindau E3 ubiquitin ligase (pVHL) which is then ubiquitinylated. The complex is thus 
targeted to the proteasome for degradation. During hypoxia, a reducing environment, the HIF-
α subunits undergo redox-dependent stabilisation and independently translocate to the 
nucleus, thus avoiding proteolytic degradation. After this nuclear translocation HIF-α can 
interact with oxygen independent HIF-1β and activate gene transcription. These two subunits 
form a complex that can bind to hypoxia-response elements (HRE). HIF-1α, induced by 
severe oxygen deprivation, and HIF-2α, induced by moderate hypoxia, are highly homologous 
proteins. They share many common HREs but some are isoform specific. Once the complex is 
bound to the HRE gene transcription is initiated. Some of the genes activated by HIFs are 
VEGF, Notch, Oct4, Nanog, HA metabolisers, CD44 and GLUT1. Genes promoting chemo-
and radioresistance are also activated. The activation of these genes contributes to cancer 
progression. The area encircled in white is still currently being researched; the individual 
elements have been examined but not altogether in the same context. Adapted from (Chilov et 
al., 1999; Krishnamachary et al., 2012; Li et al., 2009; Mimeault & Batra, 2013). 
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crucial for the development of effective cancer treatments but is beyond the scope of this 
introduction. 
 
6. Hypoxia, hyaluronan metabolism and cancer stem cells 
 
Very few studies have tried to elucidate the link between HA metabolism, hypoxia and 
CSCs (Krishnamachary et al., 2012). Most studies focused on two of these elements and 
limited themselves to briefly mentioning the remaining factor (Darzynkiewicz & Balazs, 
2012; Williams et al., 2013). Nonetheless there is ample evidence of a tie between both 
microenvironmental factors (HA and hypoxia) and CSCs. Briefly, HA metabolism as well as 
its ability to create an embryonic-like environment are highly involved in regulating the 
differentiation processes (Bourguignon et al., 2008; Charafe-Jauffret et al., 2008; 
Darzynkiewicz & Balazs, 2012; Keith & Simon, 2007; Stern, 2005). The lactate produced 
under hypoxia can stimulate HA metabolism (Stern, 2008a). HIF-1α can also directly affect 
HA metabolism by inducing the expression of CD44 or changing the proportions of standard 
and variable CD44 isoforms (Krishnamachary et al., 2012). The fact that CSCs usually 
present a CD44
+
 phenotype is further proof that HA metabolism may play an important role in 
CSC biology (Stern, 2005). Both hypoxia and HA metabolism seem to be tied to the 
acquirement of a stem cell phenotype and the persistence of CSCs, be it by altering normal 
stem cells or by inducing the acquirement of a stem cell phenotype in already differentiated 
cells. Any alteration to the pathways deemed to control the balance between symmetric and 
asymmetric divisions, and to regulate proliferation, dormancy and cell survival, can lead to 
tumour initiation, maintenance and progression (Fig. 14).  
All these elements lead to the construction of the objectives of the current research 
project. 
 
III. Objectives 
 
The study carried out throughout this Master’s Thesis aims to investigate the link 
between hypoxia, the metabolism of HA and CSCs. CSCs are implicated in both the initiation 
of tumour development and its growth and progression towards a malignant phenotype. 
Hypoxia and HA metabolism can individually impact cancer progression but it is becoming 
clear that they can act together to alter the cellular pathways of CSCs supposedly bestowing 
them with abilities associated with a more aggressive phenotype. 
We decided to isolate and study the CSCs from two different breast BC epithelial cell 
lines, MCF-7 and MDA-MB-231. The former are of luminal origin and express ER-α.  This 
cell line is not considered as possessing a particularly malignant phenotype. The MDA-MB-
231 cells are of basal origin. They do not express ER-α, progesterone receptor, or Her2 
antigen, which leads them to be known as triple negative cells. This triple negative status 
bestows them with a particularly malignant phenotype. Both cell lines form monolayers, with 
a population of cells composed of differentiated as well as undifferentiated cells. The rare 
CSC and early progenitor cells are comprised in the undifferentiated cell component. 
Many models exist to isolate CSCs but the one chosen for the current studies is the MS 
forming assay. These roughly spheric formations are initiated by a single isolated CSC or 
early progenitor cell, then grow and enrich the CSCs, and finally, over time, differentiate to 
form heterogeneous structures representing solid in vivo breast tumours. Of course this model 
does not replace the physiological environment, but it allows researchers to test the effect of 
individual and combined factors on the biology of the cells composing these three-
dimensional structures. This method of CSC enrichment via MS formation is representative of 
in vivo tumours, is ethically favourable, more cost effective and simpler to carry out than the 
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transplantation of CSCs into immunodeficient mice. The MS model makes it possible to 
explore the effects of one external factor, notably hypoxia, on MS formation and on HA 
metabolism, by investigating the changes in expression of the enzymes responsible for HA 
synthesis, HAS2 and HAS3, those responsible for HA degradation, HYAL-1 and HYAL-2, 
and the main receptor for HA and a stem cell marker, CD44, that hypoxia could induce in the 
chosen CSC model. HAS1 was not studied as previous results conducted in the laboratory 
indicated that this enzyme is not detectable in MDA-MB-231 and MCF-7 cell-lines. 
There was a certain degree of fine tuning that had to be executed, especially regarding 
the cellular density for optimal MS seeding. The results that will be presented are issued from 
these optimised seeding densities and conditions. I will not detail the preliminary 
experiments. The MSs are cultured for 4 and 7 days in normoxic or hypoxic conditions. 
Thereafter the effects of different oxygen concentrations on MS formation and on the 
mediators of HA metabolism are evaluated with multiple techniques such as MS counts, 
immunofluorescent staining, RT-qPCR analyses, western blot analyses and HA dosage. As 
the aim of the study is to check how CSCs and their HA metabolism can be altered depending 
on their oxygen environment, the results obtained with hypoxic MSs are compared to the 
normoxic MSs at the two mentioned stages of development.  
This master’s Thesis should elaborate how the metabolism of HA in CSCs is modified by 
hypoxia. This may provide us with insight on how these two factors, HA and hypoxia, may 
drive cancer initiation and progression. 
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IV. Materials and Methods 
 
A. Adherent cell lines 
 
 Two cell lines, MCF-7 and MDA-MB-231, are used for the studies. The parental cell 
lines MCF-7 and MDA-MB-231 are initially grown in adherent conditions in Dulbecco’s 
Modified Eagle Medium (DMEM) (Lonza) containing 10 % inactivated FBS (Foetal Bovine 
Serum) (Lonza) and 15 mM of Hepes buffer (Lonza). FBS inactivation is accomplished by 
incubating the serum for 30 min at 50 °C. The cells are passaged twice a week and passaging 
is limited to approximately 25 times. First the adherent cells are rinsed with 4 ml of Phosphate 
Buffer Saline (PBS). PBS is composed of KH2PO4 1.54 mM, NA2HPO4 2.7 mM and NaCl 
154 mM diluted in water and is adjusted to a pH of 7.2. 1 ml of Trypsin-EDTA (Lonza) is 
added to the monolayer and incubated at 37 °C for 5 min. The cells are resuspended in 4 ml of 
the complete DMEM medium, which also inactivates the Trypsin and then centrifuged at 200 
xg for the duration of 5 min, after which the supernatant containing the Trypsin is removed. 
The cells are resuspended in 6 ml of complete DMEM medium and seeded at the wanted 
density. The newly passaged cells are incubated at 37 °C with 5 % CO2. 
 
B. Mammosphere culture 
 
 The generation of MSs is achieved by seeding the parental cell lines, pre-incubated in 
normoxia or for 48 h in severe hypoxia, in non-adherent conditions. This is done when the 
monolayer of adherent cells has reached 80 % confluence. The non-adherent environment is 
provided by using Ultra low adherence 6-well plates (Corning) or Petri dishes coated with 
PBS-Agarose 1%. The base medium in which the cells are seeded  is composed of 
MammoCult medium basal (Stemcell Technologies) which is supplemented with 10 % 
MammoCult proliferation supplements, (Stemcell Technologies) heparin 4 µg/ml, 
hydrocortisone 0.48 µg/ml (StemCell), and L-glutamine 5 µl/ml (Glutamax 100X Gibco), is 
added. First the cells must be detached by adding 1 ml of Trypsin to MCF-7 and 1 ml of 
Accutase (Sigma) to MDA-MB-231. After 5 min of incubation at 37 °C both cell lines are 
suspended in 2 ml of MammoCult medium. The cell suspension is centrifuged at 200 xg for 5 
min after which the supernatant containing the trypsin or accutase is removed. It is vital that 
the cells are adequately dissociated, which is achieved by repeated pipetting; 40 times for the 
MCF-7 cell line and 20 times for the MDA-MB-231 cell line. By using the TC10
TM
 
automated cell counter (Bio-Rad), which counts live and dead cells, it is possible to determine 
the volume of isolated cells needed to plate the MSs at the correct concentration. The isolated 
cells are diluted in the complete medium MammoCult and seeded at the correct cellular 
density.  
 Two different cell dilutions, 1 000 and 5 000 cells per ml of MammoCult medium, are 
used to generate the MSs. Ultra low adherence 6-well plates (Corning) are used for the 1 000 
cells per ml seeding, of which the generated MSs are used for MS counts. PBS-Agarose 1 % 
coated Petri dishes are used to grow the MSs at a density of 5 000 cells per ml. These MS are 
used for immunofluorescent staining, RNA and protein assays, pH measurement of the 
medium and hyaluronic acid dosage of the medium and of the cells composing the MS. The 
MS are cultured for a total of 4 or 7 days after the initial seeding in either normoxic or 
hypoxic conditions. 
 
 
 
 Table 3. Summary of incubation durations and antibody concentrations for the 
immunofluorescent staining. AB = Antibody, BB = Blocking buffer, OV = Overnights, RT 
= Room temperature, IG = Immunoglobulins 
 
 
Staining Permeabilisation 
Aspecific binding 
blocking 
Primary AB Secondary AB 
BB Time AB 
AB 
dilution 
Time AB Dilution Fluorochrome Time 
HYAL-2 
0,5 % Triton X-
100 -PBS (5 
min) 
10 % goat 
serum- PBS – 
BSA 0.1% 
30 
min 
Rabbit anti-
HYAL-2 
0,016 
µg/µl - 
BB 
OV 
at 4 
°C 
Goat 
anti-
rabbit 
IG 
1/500 - 
BB 
Alexa Fluor-
488 
1h 
RT 
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C. Normoxic and hypoxic cultures 
 
 The adherent cell culture of both MDA-MB-231 and MCF-7 cells are cultured in 
normoxic conditions, or are incubated in severe hypoxic conditions (1 %) for 48h prior to MS 
seeding. After seeding, MSs are cultured either in normoxic conditions, 20 % O2 and 5 % CO2 
at 37 °C or in severe hypoxic conditions 1 % O2 and 5 % CO2 at 37 °C. The hypoxic 
environment is created by pumping nitrogen into a hypoxia chamber (BioSpherix) placed 
within an incubator at 20 % O2 and 5 % CO2 at 37 °C.  
 
D. Mammosphere count 
 
 The MDA-MB-231 and MCF-7 MSs seeded at a density of 1 000 cells per ml in 
Costar 6 well plates are used for the MS count. In order to carry out a count of the number of 
MSs contained in one well, the MSs are transferred with much precaution, 500 µl at a time, 
into a well of a 24-well. In order to limit the dissociation of the MSs whilst transferring them 
from one well to another, approximately 5 mm of the end of the tips of the micropipette are 
cut off before hand. MS collected after rinsing the well with 500 µl of PBS are also counted. 
In order to be counted as a MS, the formation must be composed of at least 5 cells. The 
adherent culture of MDA-MB-231 is grown in normoxic conditions, and the MS culture is 
grown in normoxia or severe hypoxia. Before seeding the MSs in normoxia or severe hypoxia 
the MCF-7 parental cell line is cultured either in normoxia or for 48 h prior to seeding in 
severe hypoxic conditions. 
 
E. Immunofluorescence 
 
 For the immunofluorescent study MSs of MDA-MB-231 and MCF-7 cells are seeded 
at a density of 5000 cells per ml in a 20 cm
2
 PBS-Agarose 1% coated Petri dish (one dish per 
condition). The MSs are first centrifuged at 15 xg for the duration of 5 min. After removal of 
the supernatant the cells are resuspended in 100 µl of PBS. The MSs are gently dissociated by 
pipetting, taking care not to damage the cells. As MSs do not adhere to glass slides they must 
first be projected onto glass slides using a Cytospin
TM
 system after which they are fixed with 
paraformaldehyde 4 % for 10 min. The slides are then rinsed with PBS two to three times 
after which the staining procedure can begin.  
 An immunofluorescent staining of HYAL2 is produced in parallel to a nucleus 
staining with TOPRO-3. The cells now fixed to the slides are first permeabilised and then 
aspecific antibody binding is blocked for 30 min in the blocking buffer. After three 5 min 
rinses with PBS the specific primary antibody can be applied. After PBS rinsing the 
secondary fluorochrome-coupled antibody directed against a species specific immunoglobulin 
is added to the slides. TOPRO-3 diluted 1/80 in PBS-RNase 2 mg / ml is applied after slide 
rinsing. The slides are then mounted in Mowiol. Table 3 summarizes the different solutions, 
antibodies, dilutions and incubation durations necessary for the immunofluorescent staining. 
 
F. Protein extraction and western blotting 
 
 MDA-MB-231 and MCF-7 MSs cultured at a density of 5000 cells per ml in normoxia 
and severe hypoxia for 4 and 7 days are collected from 3 Petri dishes. Each dish is rinsed out 
with 2 ml of PBS to insure that all MSs have been acquired. The MSs are first centrifuged at 
15 xg for 5 min after which the supernatant is removed. The cells are resuspended in 200 µl of 
PBS and transferred to an eppendorf which is centrifuged at 1 800 xg for 5 minutes. The 
supernatant is entirely discarded, and the dry cell pellet is stored at -80 °C.  
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1. Protein extraction and dosage 
 
The cell samples are lysed using 500 µl DIGE labelling buffer also known as DLA 
(Thiourea 2 M, Urea 7 M, CHAPS 4 %, Tris 30 mM, pH 8.5). This buffer also contains a 
protease inhibitor cocktail (Roche) at a concentration of 40 μl/ml. After this the sample is 
homogenised and left to incubate for 20 min on a wheel at room temperature. Next the 
samples are sonicated at a low amplitude 3 times for 10 sec. After sonication the samples are 
centrifuged for 10 min at 12 500 xg. The supernatant is delicately collected, paying attention 
not to touch the viscous pellet. A fraction of the supernatant is dosed using the Pierce 660 nm 
protein assay reagent (Thermo Scientific) in order to determine the concentration of proteins 
in each sample.  
 
2. Sample preparation 
 
15 µg of proteins are used when assaying HYAL1 and 10 µg are used for HYAL2. To 
do so the appropriate volume of the extracted protein sample is diluted in water. 5 µl of blue 
5X (Bromophenol blue, glycerol, SDS and TRIS-HCl) containing 1/20 β-mercaptoethanol is 
added, in order to weigh down the proteins and provide them with a negative charge that is 
proportional to their molecular weight. The final volume must be 40 µl. By boiling the 
samples for 3 min at 100 °C the proteins are denatured. The samples are now ready to be 
loaded into a track of a 1.5 mm Acrylamide Bisacrylamide (Bio-Rad) 10 % gel.  
 
3. Polyacrylamide gel preparation 
 
The polyacrylamide gel used for these protein assays has a thickness of 1.5mm and 
conatains 10 % Acrylamid bisacrylamid. First the running gel has to be cast. This gel is 
composed of 2.5 ml of TRIS-HCl 1.5M pH 8.8 SDS 0.4 %, 2.5 ml of Acrylamide 
Bisacrylamide 40 %, 4.5 ml distilled water, 500 µl Ammonium persulfate (Bio-Rad) and 10 
µl TEMED (Bio-Rad). As oxygen inhibits polymerisation a layer of ethanol is poured over 
the freshly cast gel. The gel polymerises after 30 min, it is at this point that the ethanol will be 
removed and the stacking gel can be cast. The stacking gel is composed of 1.25 ml of TRIS-
HCl 0.5M pH 6.8 SDS 0.4 %, 475 µl of Acrylamide Bisacrylamide 40 %, 2.9 ml distilled 
water, 375 µl Ammonium persulfate and 5 µl TEMED. Spacers are placed into the stacking 
gel in order to create tracks in which the prepared protein samples can be loaded. The stacking 
gel also takes approximately 30 min to completely polymerise. The gels can be used straight 
away or stored at 4 °C for later use. 
 
4. Protein loading and electrophoresis 
 
 The gels are placed in the electrophoresis buffer tank which is filled with the migration 
buffer (TRIS-HCl 25 mM, pH8.3, Glycine 192 mM and SDS 0.1 %). In one of the tracks 15 
µl of Protein Markers (ProSieve) is added which will form a molecular weight ladder after the 
electrophoretic migration and in the others 40 µl of the prepared protein samples are loaded. 
Migration and separation of proteins are induced by electrophoresis. Initially the migration is 
performed at 80 V for a duration of approximately 20 min, which ensures adequate stacking 
of the proteins. Afterwards the voltage is increased to 120 V. The migration is performed 
during approximately 1 h 30 min in the migration buffer. 
 
 Table 4. Summary of incubation durations, antibody dilutions and blocking solutions for 
the Western blot. Blotting solution is supplied by Roche. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PM 
(kDa) 
Primary AB Secondary AB 
Blocking Solution 
Solution for primary - and 
secondary AB dilutions  Dilution Incubation Dilution Incubation 
HYAL1 48 1 / 250 Overnight 4 °C 1 / 4 000 1 h 
Blotting solution 5 % - 
TBS- Tween 1 % 
TBS- Tween 1 % 
HYAL2 54 1 / 1 000 Overnight 4 °C 1 / 4 000 1 h 
Blotting solution 5 % - TBS 
(Abcam) - Tween 1 % 
TBS (Abcam)- Tween 1 % 
Actin 43 1 / 100 000 30 min 1 / 4 000 45 min 
Blotting solution 5 % - 
PBS- Tween 1 % 
PBS- Tween 1 % 
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5. Semi-humid transfer 
 
After the molecular weight-specific separation induced by electrophoresis, the proteins 
that are contained in the gel are transferred to a polyvinylidene difluoride (PVDF) membrane 
using a semi-humid method. The PVDF membrane is soaked for 15 sec in methanol 100 % 
and then conditioned for 10 min in a transfer buffer (TRIS-HCl 2.5mM pH 8.3, Glycine 
192mM, methanol 20 % ). For each gel 6 pieces of Whatman paper is needed. These sheets 
are soaked in the transfer buffer. 3 of the sheets are stacked on the tray of the machine that 
will supply the electric current necessary for the transfer. Consecutively the PVDF membrane 
is placed on the Wathman paper, the gel with the migrated proteins and finally the 3 
remaining sheets are stacked on top. The transfer is performed in the 20 % methanol Tris-
Glycine buffer and is performed for the duration of 1 h 30 min. The transfer machine is set to 
60 mA per PVDF membrane and 20 V which is independent of the number of PVDF 
membranes used. 
 
6. Protein detection  
 
 After the transfer the protein of interest and a protein for normalisation, in this case 
actin, can be detected by the use of antibodies combined with chemiluminescence. First 
nonspecific antibody binding is blocked by incubating the PVDF membrane with Roche’s 
chemiluminescence supplied blocking reagent diluted to 1 % in Tris Buffer saline (TBS) 
(Abcam) containing 0.1 % Tween. The membrane is then rinsed repeatedly for 30 min. A 
rabbit produced primary polyclonal antibody against HYAL1 (Sigma) or HYAL2 (Abcam) is 
added and left to incubate at 4 °C overnight. The membrane must thereafter be washed 
repeatedly for 30 min with the adequate buffer (PBS- or TBS- Tween 1 %). The membrane is 
then incubated with a goat produced secondary antibody directed against rabbit 
immunoglobulins. This antibody is coupled to horseradish peroxidase (HRP) which catalyzes 
a light emitting reaction once the luminescence substrate has been added. This emission of 
light is detectable by photographic films or phosphor-imaging screens. Both of these 
antibodies are diluted in 0.5 % blocking reagent – TBS – 0.1 % Tween. The proteins are now 
detectable via the emission of luminescence. In the dark room a film is placed on top the 
membrane to which the luminescence substrate has been added. The film is exposed for a 
certain duration after which the film is developed. Bands proportional to the quantity of the 
protein of interest should appear on the film after development. Next the membrane is 
incubated with the primary antibody directed against actin that is produced in the mouse. Thus 
the secondary antibody is an anti-mouse immunoglobulin antibody. Both of these antibodies 
are diluted in the 1 % blocking reagent – PBS –0.1 % Tween. By adding the HRP substrate 
light will be emitted by any secondary antibodies that have bound to the membrane. Again the 
quantity of protein can be revealed by exposing photographic film to the light emitting 
membranes. After this a semi-quantative study of the expression of the protein of interest is 
enabled. The protein of interest is normalised to the abundance of actin. Table 4 shows a 
summary of the antibodies and incubation durations used. 
 
G. RNA extraction and Real-time reverse-transcription PCR 
 
 MDA-MB-231 and MCF-7 MSs grown in normoxia and severe hypoxia are recovered 
from 3 Petri dishes at 4 and 7 days, and are each rinsed out with 2 ml of PBS. After a 5 min 
round of centrifugation at 15 xg, the supernatant is removed and the MSs are resuspended in 
500 µl of TRI Reagent (Sigma) and stored at – 80 °C until needed for RNA extraction.  
 
 Forward primer (5' - 3') Reverse primer (5' - 3') 
HAS2 CCTCATCATCCAAAGCCTGT GATGCAAAGGGCAACTGTTT 
HAS3 GCCCTCGGCGATTCG TGGATCCAGCACAGTGTCAGA 
CD44 CATTGCAGTCAACAGTCGAAGAA ATTGCCACTGTTGATCACTAGCTT 
Actin CTGCTACCAGGACACGATTT CCCTTACACATCGGAGAACAG 
 
Table 5. Primer sequences for RT-qPCR 
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1. RNA extraction 
 
The RNA extraction is conducted in RNase free conditions. After homogenisation the 
samples are incubated for 5 min at room temperature, then 100 µl of chloroform is added and 
the tubes are briefly vortexed. The specimens are centrifuged at 12 000 xg for 15 min at 4 °C. 
The aqueous phase is recovered and the rest is discarded. The next steps of the RNA 
extraction follow the protocol of the RNeasy minElute Cleanupkit (QIAGEN). First 300 µl of 
ethanol 70 % is applied and mixed by pipetting then the sample is transferred to a 2 ml 
RNeasy MinElute spin column. The tubes are centrifuged at 7 400 xg for 15 sec after which 
the flow-through is discarded. Next 500 µl of the supplied RPE buffer is added and 
centrifuged for 15 sec at 7 400 xg. 500 µl of ethanol 80 % is applied to the spin column and is 
then centrifuged for 2 min at 7 400 xg. The spin column is then placed in a new collection 
tube, with the lid open, and is centrifuged for 5 min at full speed. After discarding the flow-
through the column is placed in a new 1.5 ml collection tube. 20 µl of RNase-free water is 
applied directly to the centre of the spin column membrane and is then centrifuged at full 
speed for 1 min in order to elute the RNA. The flow-through is reapplied to the spin column 
membrane and centrifuged another time, which insures that all the RNA has properly 
detached from the membrane and eluted into the collection tube. The RNA obtained from this 
extraction can be quantified using the Nanodrop, which determines the concentration on the 
basis of spectra absorption at 260 nm.  
  
2. Retro-transcription and quantitative PCR (RT-qPCR) 
 
The qRT-PCR is accomplished in two steps. The extracted RNA, which can be stored 
at -80 °C until needed, is retro-transcribed into cDNA. To this purpose a volume containing 
0.5 µg of RNA is added to an eppendorf to which a certain volume of RNase free water is 
added in order to come to a final volume of 13 µl. The samples are heated for 10 min at 70 °C 
and thereafter put on ice. The retro-transcription is carried out by adding 4 µl of M MLV-
RTase Buffer (Promega), 1 µl dNTP 10 mM (Promega), 1 µl of Random hexamers 
(Invitrogen) diluted 10x and 1 µl of M MLV-RTase (Promega) (kept on ice) to each sample. 
The specimens are then placed into a thermal cycler that effectuates a single cycle of 5 min at 
25 °C, 60 min at 42 °C and finally 5 min at 95 °C. The samples are stored at 4 °C or directly 
used for the PCR.  
 For the second step of the PCR, the obtained cDNA is diluted 10x in RNase free 
water. 5 µl of the cDNA is then deposited into a well of a 96-well PCR plate. To each well 
containing cDNA 10 µl of Sybrgreen, 2.5 µl of the forward primer and 2.5 µl of the reverse 
primer of the gene of interest are added. The primers have a final concentration of 0.3 µM. 
Every condition is done in triplicates. The plate is centrifuged at 295 xg for 3 min after having 
been sealed with a thermal seal. The plate is then introduced into the thermal cycler for 2 min 
at 50 °C, 10 min at 95 °C and 40 cycles of 15 sec at 95 °C and 1 min at 60 °C. For the primer 
sequences see Table 5. 
 
H. PH measurement 
 
 The medium of MDA-MB-231 and MCF-7 MSs cultured for 4 and 7 days in normoxic 
or severe hypoxic conditions is collected after centrifugation at 15 xg for 5 min. The pH of the 
medium is then directly measured with a pH meter. 
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I. Hyaluronic acid dosage 
 
1. Sample preparation 
 
 The dosage of HA is carried out on MS obtained after having been cultured for 4 and 7 
days in either normoxia or hypoxia. A total of 4 PBS-Agarose 1% coated Petri dishes 
containing MDA-MB-231 MSs seeded at a density of 5 000 cells/ml are needed for each 
condition.  
 The day prior to MS collection (third day for MSs collected at developmental day 4, 
and the sixth day for MSs collected at developmental day 7) the medium containing the 
spheres of each individual condition is collected and pooled. The Petri dishes are each rinsed 
with 5 ml of PBS after which the solution is also collected, in order to recover any remaining 
MSs. The samples are then centrifuged at 15 xg for the duration of 5 min. The supernatant is 
discarded and the MSs are gently resuspended in a total volume of 10 ml of complete 
MammoCult medium. The resuspended MSs are then reseeded in 1 Petri dish per condition. 
This precaution is performed in order to be able to study the 24 hour production of HA by the 
MSs at developmental day 4 and 7 in normoxia or hypoxia. At seeding day 4 and 7 the 
medium containing the pooled MSs is collected. The Petri dishes are rinsed with 2 ml of PBS 
and collected. The samples are centrifuged at 200 xg for 5 min after which the supernatant is 
kept and stored at – 20 °C. The pellet of MSs is resuspended in 200 µl of PBS. 170 µl of the 
sample is transferred to an eppendorf with a screw-top which will be used for the HA dosage 
within the cell fraction, and the remaining 30 µl is transferred to an eppendorf for protein 
dosage. The protein dosage is used later on for the normalisation of the results. Both sets of 
eppendorfs are centrifuged at 1 800 xg for 5 min. The supernatant is then removed from each 
sample. The fractions destined for the protein dosage are stored at -80 °C. The cell fractions 
which will be used for the HA dosage are resuspended in 100 µl of TRIS HCL 0.1 M CaCl2 
10 mM and 11 µl of Pronase (Sigma). The addition of pronase is necessary for the cellular 
fraction as it will degrade any proteins that may be holding HA, thus allowing its liberation. 
Next they are incubated for 24 h at 55 °C on a wheel. After the 24 h incubation period the 
samples are boiled for 10 min and then stored at -20 °C until needed for the HA dosage. 
 
2. Dosage of hyaluronic acid 
 
By using the Hyaluronan Duo Set Kit (R & D Systems) the quantity of HA in the 
cellular fractions and that that is released into the medium can be dosed. The evening before 
the HA dosage, 96-well microplates must be coated with 50 µl of a Capture Reagent, made up 
of Aggrecans diluted in PBS. The plates are sealed and left to incubate at room temperature 
overnight. The wells are rinsed out three times with a Wash Buffer (PBS 0.05 % - Tween 20), 
during this process it’s important that all the liquid be removed. Next the wells are blocked 
with the Blocking Buffer (PBS 0.5 % - Tween 20 NaN3) for 1 h at room temperature. The 
plates are now rinsed three times after which the plates are ready to receive the sample. The 
samples and the standards are diluted in the Reagent Diluent (PBS 5 % - Tween 20) after 
which 50 µl are deposited into each well. The plates are covered and left to incubate for 2 h at 
room temperature. The plates are rinsed three times, and then 100 µl of the Detection 
Reagent, composed of biotinylated aggrecans, is added to each well which is then incubated 
for the duration of 2 h at room temperature. The plates are washed after which 50 µl of 
Streptavidin-HRP is deposited into each well. The plates are covered and incubated for 20 
min at room temperature. The plates should be kept out of direct light. After rinsing the wells 
three times, 50 µl of the Substrate Solution is added and left to incubate for 20 min. By adding 
the Substrate Solution the colorimetric reaction induced by the HRP activity is initiated. The 
 Figure 15. DuoSet ELISA Development Systems Assay Princple. This figure represents 
the procedure for the HA dosage. In a first step the analyte, in this case HA, will bind to the 
aggrecans present on the plate. In step 2 the biotinylated aggrecans are added which will bind 
to the HA already bound to the plate. Step 3, streptavidin coupled to HRP is added which will 
bind to the aggrecans. In step 4 the HRP substrate is added, inducing a colorimetric reaction. 
By binding to the biotinylated aggrecan the quantity of HA can be measured, as the HRP 
induced colour change is proportional to the amount of HA present in the well. The Stop 
solution blocks the colorimetric reaction and provokes a colour change, turning it to yellow 
which is detectable at 450 nm. The obtained values are normalised to the protein fractions 
collected in parallel to the cellular fractions and medium. (Images acquired from 
http://www.rndsystems.com) 
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plates must yet again be sheltered from direct light. 25 µl of Stop Solution, composed of 
H2SO4, is added to each well, which is well mixed by gently tapping on the plates. This 
solution stops the colorimetric reaction, thus allowing a spectrophotometric measurement of 
the optical density for each individual well by using a microplate reader at 450 nm. This 
procedure enables an evaluation of the quantity of HA present in the cellular fractions and the 
medium in which the MSs were cultured.  
In a first step the HA will bind to the aggrecans present on the plate. After the rinses 
biotinylated aggrecans are added which will bind to the HA already bound to the plate. Next 
streptavidin coupled to HRP is added which will bind to the aggrecans. The colorimetric 
reaction is induced by addition of the HRP substrate. By binding to the biotinylated aggrecan 
the quantity of HA can be measured, as the HRP induced colour change is proportional to the 
amount of HA present in the well. The Stop solution blocks the colorimetric reaction and 
provokes a colour change, turning it to yellow which is detectable at 450 nm. The obtained 
values are normalised to the protein fractions collected in parallel to the cellular fractions and 
medium (Fig. 15).   
 
  
Figure 16A. Phase contrast 
microscopic imaging of MSs 
grown in normoxia or severe 
hypoxia at different 
developmental stages. (A-D) 
depict MDA-MB-231 MSs and 
(E-H) MCF-7 MS. In (A, C, E, 
and G) are the normoxic MS of 
the respective cell-line, in (B, 
D, F and H) are the hypoxic 
MSs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16B. Phase contrast 
microscopic imaging of 4 day 
MCF-7 MS after different 
pre-treatments and MS 
seeding conditions. (A) 
represents normoxic MSs issued 
from a normoxia treated 
adherent cell-line. (B) Depicts 
hypoxic MSs issued from an 
adherent culture pre-treated with 
normoxia. (C) Normoxic MSs 
obtained from hypoxia pre-
treated parental cells are 
vifsible. (D) Schows MSs grown 
and pre-treated with hypoxia. 
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V. Results and discussion  
 
A. Effect of hypoxia on the morphology of mammospheres 
 
 Phase-contrast microscopy imaging reveals the morphology of the MDA-MB-231 and 
MCF-7 MSs cultured in normoxic or severe hypoxic conditions at two different develop-
mental stages, 4 and 7 days (Fig. 16A). The adherent culture is seeded at a density of 1000 
cells/ml of medium in order to carry out the study of MS morphology. 
 The MSs formed by MDA-MB-231 cells appear to be quite loose and are very fragile. 
Their shape is random and the individual cells composing the sphere are well distinguished. 
These MSs can easily be dissociated, requiring any manipulations of these formations to be 
undertaken with a light touch. Based on repeated observations, the size of the normoxic 
spheres appears to be slightly smaller at developmental day 7 than at day 4. The hypoxic MSs, 
on the other hand, seem to moderately increase in size over the same time period. There is no 
particular difference that can be made between the normoxic and hypoxic MSs after 4 days. 
At developmental day 7 the hypoxic MSs have a considerably greater size than the normoxic 
MSs. 
 By contrast, MCF-7 MSs form dense regular spherical structures. The cells composing 
the spheres cannot be distinguished very easily; the cells seem to be tightly attached, giving 
the formation a more compact appearance than compared to the MSs formed by the MDA-
MB-231 cell-line. The MCF-7 spheres are robust and are not easily dissociated. An increase 
in the size of the MSs can be observed over the course of time. In this cell line the MS 
morphology does not appear to be affected by the oxygen concentration as is the case in 
MDA-MB-231 MSs.  
 Additionally the impact of a 2 day pre-incubation in normoxia or hypoxia of the MCF-
7 adherent cell cultures has been investigated. The microscopic imaging of such pre-treated 
parental cells subsequently cultured in MS forming conditions for a period of 4 days reveals 
that the size, shape and density of the MSs cultured in these 4 different combinations of 
oxygen conditions appear to be the same (Fig. 16B). No apparent effect of these pre-
treatments on the morphology of the MCF-7 MSs can be observed whether they are cultured 
in normoxia or hypoxia. 
 These results indicate that the MSs formed by MDA-MB-231 and MCF-7 cells do not 
have the same response to hypoxia. Only the MDA-MB-231 MSs appear affected in their 
shape by the concentration of oxygen available. The reason for the differing response to 
hypoxia is not understood. It is obvious that this hypoxic effect could simply be cell line 
dependent. It could be due to proliferation differences in response to the oxygen environment. 
A recent paper by Harrison et al. evokes the importance of the presence or absence of ER-α 
expression on the CSC responsiveness to hypoxia (Harrison et al., 2012). The authors 
demonstrated a HIF-1-dependent CSC increase in ER- positive cell lines and cancers 
following hypoxic exposure, which was blocked by inhibition of oestrogen and Notch 
signalling. A contrasting decrease in CSC was seen in ER- negative cell lines and cancers. 
Harrison’s paper emits the hypothesis that ER-α positive cells, such as the MCF-7 cell-line, 
have altered self-renewal and increased dedifferentiation in response to hypoxia, whereas the 
ER-α negative cells, like the MDA-MB-231 cell-line, have altered proliferation pathways. 
Therefore, not only the proportion of CSCs contained in these formations but also the 
composition of their differentiated cells could be affected by the oxygen environment. 
Consequently one could consider that MSs could have a greater size, without affecting the 
number of spheres in the plate, if there is a higher proportion of proliferating cells or if 
proliferation is activated by hypoxia (e.g. in MDA-MB-231 cells). To confirm this hypothesis 
proliferation could be measured by analysing the abundance of Ki67, which is a well-known 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Fold change in MS formation in different oxygen concentrations. Comparisons 
are made to the strictly normoxic MS formations. (A and B) Represent the fold change in 
MDA-MB-231 MS formation and (B and C) the MCF-7 MS formation after respectively 4 
and 7 days in culture. (E) Represents the 4 day MCF-7 MS fold change after pre-treating the 
adherent cell-line and then seeding the isolated cells with different combinations of oxygen 
concentration. The analyses are carried out using a two-way ANOVA with Bonferroni 
posttests. (* = P< 0.05 and ns = non significant) 
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proliferation marker. A verification that the MCF-7 cell line we use does indeed express ER-α 
and that the MDA-MB-231 cell line does not was carried out and confirmed by a colleague. 
 Another possibility for the increased size of hypoxic MDA-MB-231 MSs at 7 days is a 
stronger interaction between cells, thus reducing the number of cells that get detached from 
the formation. Indeed it is known that hypoxia, through the intermediate of HIFs, can affect 
proteins involved in cellular adhesion and can modify the ECM (Harris, 2002). CD44 is a 
glycoprotein that is involved in cellular interactions and that is differently expressed in 
response to hypoxia. The cell-cell and cell-ECM interactions mediated through CD44 and HA 
can also modify the cancer cells’ survival mechanisms. This could contribute to an increased 
MS size due to a larger proportion of cells surviving in the hypoxic conditions (Bourguignon 
et al., 2009; Toole, 2004). The expression of CD44 has been investigated during this study 
and will be detailed later on (no significant difference was observed, however). An alteration 
of the ECM due to a different abundance of HA could also provoke a change in the 
morphology of the MSs. A dosage to determine the quantity of HA released into the medium 
and present in the cellular fraction has also been carried out throughout this study and will be 
discussed later (an increased HA production during hypoxia in MDA-MB-231 but not in 
MCF-7 MSs was confirmed). 
 
B. Effect of different oxygen concentrations on mammosphere formation 
 
 The number of MSs formed by both cell lines seeded in non-adherent conditions at a 
density of 1000 cells/ml is a method of representing early stem cell or progenitor activity. It 
indicates how well the CSCs issued from the adherent cell cultures survive in suspension. It is 
important to note that this method does not provide any information on the self-renewal 
capacity of the stem cells. By seeding the cells in different oxygen conditions it may be 
possible to determine which oxygen concentration is more favourable to MS formation. The 
results depicted in Fig. 17 (A-D) represent the fold induction of MS formation, when 
compared to one chosen normoxic replicate at developmental days 4 and 7. An unpaired t test 
was utilised in order to determine whether the fold inductions between normoxic and hypoxic 
MSs are significantly different. 
 In MDA-MB-231 MSs there is no observable difference between the formations of 
MS depending on whether the cells were seeded in normoxic or hypoxic conditions at 
developmental days 4 and 7. However, counting MDA-MB-231 MSs is delicate work as the 
formations are extremely fragile. During the transfers from the 6-well plates to the 24-well 
plates it is possible that the spheres are broken, biasing the number of MSs counted. To avoid 
the problems of mechanical handling it was attempted to seed the spheres directly onto PBS-
agarose 1% coated 24-well plates. However, this method comes with the disadvantage that the 
MSs are found concentrated in the middle, making it difficult to single out the individual 
MSs. 
 The MSs formed by MCF-7 cells are more resistant, thus transferring them from one 
well to another does not cause a significant amount of manipulation induced dissociation. 
Proportionally to normoxia the initiation of MS formation by MCF-7 cells does not appear to 
be affected by hypoxia after 4 days in normoxic or hypoxic conditions although there is an 
insignificant tendency to an increase in hypoxic MS formation. This non-significant 
difference between MS growth in normoxia and hypoxia is maintained throughout both 
developmental stages. 
 Due to the technical difficulties in studying the number of MDA-MB-231 MSs and the 
considerable financial aspect of each seeding, it was deemed appropriate to further inquire the 
effects of hypoxia on MS formation in solely the MCF-7 cell-line (Fig. 17E). In these studies 
on MCF-7 cells the influence of pre-treating the parental cell line with different oxygen 
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conditions before seeding the cells in normoxic or hypoxic MS forming conditions was 
explored. These MSs were then cultured for 4 days in the specific oxygen condition. As 
previously mentioned the adherent cultures pre-treated in normoxia and then seeded in 
normoxia (normoxia to normoxia) or hypoxia (normoxia to hypoxia) do not bear a significant 
difference in fold change of MS formation. Pre-treatment of the MCF-7 parental line in 
hypoxia does not significantly influence the fold change in the number of MSs formed in 
normoxia (hypoxia to normoxia) although a slight tendency to increase can be observed. The 
adherent cells pre-treated in hypoxia and then seeded into a hypoxic MS forming environment 
(hypoxia to hypoxia) have a significantly increased number of MSs compared to the normoxic 
MSs. 
 In summary, only when both the pre-treatment and the seeding conditions are at a low 
oxygen concentration is a significant increase in MCF-7 (but not in MDA-MB-231) MS 
formation observed when compared to the strictly normoxic MSs. This phenomenon has not 
been described in the literature yet. The results published by Harrison et al. (increase in MS 
formation in the hypoxic to normoxic condition) have not been reproduced in this study but it 
must be noted that the seeding conditions are not entirely equal. For instance, there are 
differences in the medium used and in the incubation durations.  
 The increased MS formation in the hypoxic pre-treated MSs cultured in hypoxia could 
be due to an increase in the proportion of CSC present in the total adherent population of 
cells. It could also be due to the fact that hypoxia favours the initiation of MS formation. The 
fact that no increase in MS formation occurs in the normoxic MSs issued from a hypoxic pre-
incubation indicates that the presence of a hypoxic environment in the adherent culture on its 
own does not favourably affect the cellular processes of CSCs seeded in normoxia. But it 
mainly indicates that it probably isn’t the proportion of MS that is modified by this pre-
treatment. If this had been the case an increase in MS formation should have been observed in 
the hypoxic to normoxic conditions. Thus, the hypoxic treatment prior to anchorage 
independent growth may in a way condition the CSCs to better survive in the hypoxic 
environment. The hypoxic environment can thus be favourable under the condition that the 
CSCs have already been subjected to these low oxygen conditions. In a similar fashion, Louie 
et al. have shown that repetitive cycles of hypoxia and re-oxygenation but not short bouts of 
hypoxia are able to increase the proportion of CSCs in two BC cell lines, MDA-MB-231 
(where we did not test the effect of hypoxic pre-incubation) and BCM2 (Louie et al., 2010). 
 Thus, the particular effects of different exposures to hypoxia may modulate the CSC 
subpopulation in human BC. It would be useful to see whether the hypoxic effect we observed 
is MCF-7 cell line specific or whether it occurs in other BC cell lines. As Harrison et al. 
evoke that the response to hypoxia is mediated by the ER-α status it would be interesting to 
inspect this too. To do so one could use multiple cell lines from ER-α positive and ER-α 
negative cells that would be seeded in the various oxygen concentration combinations. To 
determine the implication of the ER-α status on the response to hypoxia, the receptor could be 
knocked down in ER-α positive cells, and, vice versa, the ER-α negative cell lines could be 
transfected with the gene. Secondary sphere formation could also provide additional 
information, such as whether it is the self-renewal processes that are affected by hypoxia. 
Further investigation aiming to uncover the mechanisms underlying the increased potency to 
form MS in these strictly hypoxic conditions would constitute compelling work that could be 
performed in the future. 
 
C. The effect of hypoxia on the pH of the mammosphere culture medium 
 
The pH of the media collected from MDA-MB-231 and MCF-7 MSs was measured at 
day 4 and 7 of their development.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. pH values of the medium in which the MSs were cultured. (A) Represents the 
pH of the MS medium issued from MDA-MB-231 MS cultured in normoxia or severe 
hypoxia for 4 and 7 days. (B) Shows the pH values of the medium of MCF-7 MSs cultured in 
normoxia or hypoxia for 4 and 7 days. 
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 The MSs formed by MDA-MB-231 do not show any specific change in pH throughout 
the development of the spheres, in both normoxic and hypoxic conditions (Fig. 18). The pH 
remains within the neutral range. The curve representing the pH of the hypoxic MSs is lower 
than that of the normoxic MS and this difference is significant. This is valid for both 
developmental stages. The measured pH is considered as neutral in both conditions. Almost 
identical observations are made with MCF-7 MS cultures. 
 These results indicate that either hypoxia itself or the hypoxic MSs induce a slight 
reduction of pH of the medium, although this reduction is significant only for the MDA-MB-
231 cell line. The pH of the medium is contained in the neutral pH range for both cell lines 
and in both conditions. 
 Tumour masses usually have a lower pH than normal non malignant tissue, and cells 
exposed to hypoxia can also have a low pH due to the altered metabolism (Al Okail, 2010; 
Tannock, Rotin, & Hot, 1989). Thus it’s not surprising to see that the pH diminishes in 
hypoxia. Due to the fact that the medium contains buffers that stabilise the pH a titration of 
the medium would have had to be performed in order to determine to what extent the hypoxic 
MSs manage to induce a reduction of pH of the medium. The reduced pH of the medium may 
indicate that the cells are exchanging protons in order to reduce extent of intracellular 
acidosis, which is common in cancer cells but can be exasperated by hypoxia. Further studies 
could be performed in order to determine whether the cells are indeed in acidosis. One of the 
molecules involved in acidosis that is highly produced in cancer cells through the altered 
metabolism is lactate. Lactate is involved in many cellular processes and can impact cancer 
progression. Promotion of metastasis can be mediated through lactate induced HA secretion 
by tumour associated fibroblasts, cellular migration can be stimulated, and the anti-oxidative 
properties of lactate can offer radio-resistance to the cancer cells (Hirschhaeuser et al., 2011). 
The expression of many mediators of HA metabolism can be stimulated by lactate. This 
indicates that a dosage of lactate could offer some insight to any changes in HA metabolism 
that could arise in cancer cells, especially when exposed to hypoxia. 
   
D. Effect of different oxygen concentrations on the metabolism of hyaluronan 
 
1. Effect of hypoxia on the production and secretion of hyaluronan 
 
 The effect of the oxygen environment is studied at two developmental stages in MDA-
MB-231 MSs and MCF-7 MSs. The quantity of HA present in the cellular fraction is 
measured as well as that released into the medium over a 24 h period. The HA measured in 
the cellular fraction corresponds to that contained within the cell, but also that bound to the 
cell. The statistical analyses are only possible for the MDA-MB-231 MSs as there is at least 
one replicate missing from the MCF-7 MSs (Fig. 19).  
 The production of HA in the cellular fraction of MDA-MB-231 MSs does not appear 
to vary over the course of time in normoxia. In hypoxia the production of HA also appears to 
remain consistent over the course of time. At day 4 there is a higher HA production in 
hypoxic MSs compared to those in normoxia. At this developmental stage the difference is 
significant. At 7 days the hypoxic MSs appear do not present a significant difference in the 
production of HA compared to the HA production normoxia, but the variability is rather high 
at this developmental stage making it difficult to draw any specific conclusions. 
 The release of HA into the medium by MDA-MB-231 in both normoxia and hypoxia 
appears to increase after 7 days in culture. The secretion of HA in normoxic and hypoxic MSs 
at developmental day 4 and 7 appears to bear a tendency to be higher in the medium of the 
hypoxic MSs. 
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Figure 19. Dosage of the HA in the cellular fractions and in the medium of MS cultured 
in different oxygen conditions and at different developmental stages. (A and C) represents 
the quantity of HA produced in 24h in the cellular fraction of MS at two developmental 
stages. (B and D) depict the quantity of HA released into the medium during 24 h by 
normoxic and hypoxic MSs at two developmental stages. The data collected for MDA-MB-
231 (A and B) MSs is issued from 3 separate replicates, and that of the MCF-7 MSs (C and 
D) is issued from 2 replicates. Statistical analysis will only be possible for the MDA-MB-231 
cell-line due to missing replicates for the MCF-7 cell-line. The MDA-MB-231 data is 
analysed using a two-way ANOVA with a Bonferroni posttest. The quantity of HA is 
normalised to the quantity of proteins of each sample. (* = p < 0.05) 
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 Regarding the MCF-7 cell line, the production of HA in the cellular fraction of the 
MSs appears to remain unvaried over time in normoxia and hypoxia. The production of HA 
seems to be lower in hypoxic MS after 4 days in culture than that of normoxic MSs. This 
tendency to a reduced quantity of HA seems to be maintained at developmental day 7. 
 The release of HA into the medium by MCF-7 MS appears to decrease over time in 
normoxic conditions, whereas it appears to remain unvaried in the hypoxic conditions. At 
developmental day 4 the release of HA does not show any particular difference between the 
normoxic and hypoxic MSs. At developmental day 7 no difference in HA release can be made 
either between normoxic and hypoxic MSs. 
 In summary, hypoxia has a moderately stimulating effect on the production of HA and 
on its release into the medium in MDA-MB-231 MS cells but not in MCF-7 MSs. This 
increased synthesis could be caused by an increased expression of the HA synthesising 
enzymes, such as HAS2 and HAS3. The expression of the genes coding for HAS2 and HAS3 
are studied at the transcriptional level and will be detailed in the coming paragraphs. Previous 
studies conducted in the laboratory indicate that HAS1 is not expressed in MDA-MB-231 and 
MCF-7 MSs, thus the study of this protein is excluded from this Master’s Thesis. In the 
MDA-MB-231 cell line the different levels of production and release of HA in hypoxia could 
also be due to differences in the activity of the HAS enzymes that could possibly be induced 
by hypoxia. The study of the activity of these enzymes was not achievable during this 
particular research but could be an avenue worth exploring in the future. A higher number of 
replicates would be of interest as the variability is quite high. The fact that the quantity of HA 
appears to have a tendency to increase in hypoxia could also be caused by a slower turnover 
rate, meaning that the HYALs could be less active or their expression diminished. 
 It seems that hypoxia has an opposing effect (or at least an opposing trend) on the 
production and release of HA in the MCF-7 MSs than that seen in MDA-MB-231 MSs. The 
release of HA into the medium does not appear to be affected by the oxygen concentration. In 
MCF-7 MSs hypoxia does appear to affect the production of HA in the cellular fraction as 
they reveal a slight tendency to have a reduced secretion of HA compared to that of the 
normoxic MS. Due to insufficient data it is not possible to tell whether the decrease in severe 
hypoxic conditions is merely a tendency or whether it represents an actual significant 
decrease. This reduced production of HA could be caused by a reduction in the expression of 
HAS proteins. The transcriptional expression has been studied and will be described later on. 
It is also possible that the decrease is a consequence of a reduced activity of the enzyme, 
which may be caused by the hypoxic conditions. The tendency to a reduction in HA quantities 
may also be caused by different expression levels and activities of HYALs. 
 Looking into the cellular mechanisms leading to the fact that HA production in these 
two cell lines is differently affected by hypoxia could also amount to some interesting work. 
Evidently it would also be fascinating to determine whether the abundance of the different 
HA fragment sizes is altered by the oxygen environment. As mentioned in the introduction, 
the physiological action that HA can have on the physiology of a cell and how it can 
contribute to cancer biology is dependent on the size of the fragments. Studying this could be 
achieved by dosing the quantity of HA after having separated the fragments of HA using size-
exclusion chromatography. 
 
2. CD44 expression in different oxygen conditions 
 
 The effect of the oxygen environment on the expression of CD44, a stem cell marker 
and also the main receptor for HA, is studied in MDA-MB-231 and MCF-7 MSs at two 
developmental stages. Four and three replicates have been gathered for MDA-MB-231 and 
MCF-7 MS RT-qPCR analyses, respectively (Fig. 20).  
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Figure 20. Fold change in transcriptional expression of CD44 in MS cultured for 4 and 7 
days in normoxia or hypoxia. (A and B) represent MDA-MB-231 cell-lines, values were 
obtained from 4 individual replicates. (C and D) represent MCF-7 cell-lines, for which 3 
replicates were used. The values are normalised to actin expression. The statistical analyses 
were carried using a two-way ANOVA with Bonferroni posttests. The analysis is performed 
on the ΔCT and the graphs show the fold change (2-ΔΔCT). (ns = non significant).  
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 In MDA-MB-231 MSs, the expression of CD44, assessed through RT-qPCR, shows a 
tendency to increase over time, from 4 to 7 days in culture. After 4 days in culture the 
expression of CD44 does not reveal any differences between the two oxygen conditions. After 
7 days of culture no difference in expression of the HA receptor can be detected either. The 
variability at developmental day 7 is considerable, evoking the fact that additional replicates 
should be added in order to better assess the variation in transcriptional CD44 expression 
between both conditions. 
 RT-qPCR measurements of CD44 expression in MCF-7 MSs seem to reveal a 
diminishment in expression in both oxygen conditions over time. At developmental day 4 the 
expression of CD44 does not show any statistical difference between both oxygen conditions; 
this is also the case at developmental day 7 although there does seem to be a tendency to a 
lesser expression in the hypoxic MSs compared to the normoxic MSs. Again the variability is 
rather high. 
 The fact that no significant difference in the expression of CD44 can be detected 
between the normoxic and hypoxic MSs is somewhat surprising as a publication in literature 
evokes that hypoxia via the intermediate of HIF up-regulates CD44 expression 
(Krishnamachary et al., 2012). There are a couple of possibilities that could explain this 
discrepancy. First of all CD44 expression seems to evolve throughout time. For example in 
the MCF-7 cell line a tendency to a diminishment in CD44 expression can be seen throughout 
the development. It might be that any effects of the oxygen expression on CD44 in MSs could 
have occurred prior to day 4. Thus studying the effect that normoxia and hypoxia could have 
on CD44 expression at an earlier stage, closer to the initiation of the MSs, would be 
interesting. This exact phenomenon has been observed in unpublished studies performed by a 
colleague working in the same MS forming conditions in the laboratory. RT-qPCR performed 
on MCF-7 MS at developmental day 2 reveal a 5-fold increase in CD44 expression in the 
hypoxic MSs (identical sense and anti-sense primers were used for both studies).  
 The RT-qPCR study carried out on the expression of CD44 is performed using primers 
that have a ubiquitous recognition of CD44 isoforms. Studying whether the oxygen 
concentration has an influence on specific splice variants could be an avenue worth exploring, 
especially as there is a link between poor patient outcome and a higher abundance of the 
alternative splice forms such as CD44v3 and v6 in comparison to the standard CD44 splice 
form. With the chosen method of CD44 expression throughout this particular study such 
differences are not detectable. 
 
3. HAS2 expression in different oxygen conditions 
 
The expression of HAS2 has been analysed in MSs cultured in normoxia and severe 
hypoxia at 2 different developmental stages by RT-qPCR (Fig. 21).  
The focus will first be set on MDA-MB-231 MSs. There is a significant increase in 
HAS2 expression over the course of time in the hypoxic MSs when compared to that of the 
normoxic MSs. Both of the studied variables, notably the oxygen concentration and the days 
in culture, have a significant effect on the expression of HAS2. At developmental day 4 there 
is a non-significant tendency to an increase in mRNA for HAS2 in the hypoxic condition. At 
developmental day 7 this hypoxic tendency to an elevated expression becomes statistically 
significant when compared to the normoxic condition. 
The expression of HAS2 in MCF-7 MSs does not appear to evolve between 4 and 7 
days after seeding, in both the normoxic and hypoxic environment. At developmental day 4 
and 7 there is no particular difference in expression that can be made evident between the 
normoxic and hypoxic seeding conditions. However, variability is high and the number of 
experiments (n = 3) is limited. 
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Figure 21. Fold change in transcriptional expression of HAS2 in MS cultured for 4 and 7 
days in normoxia or hypoxia. (A and B) represent MDA-MB-231 cell-lines, values were 
obtained from 4 individual replicates. (C and D) represent MCF-7 cell-lines, for which 3 
replicates were used. The values are normalised to actin expression. The statistical analyses 
were carried using a two-way ANOVA with Bonferroni posttests. The analysis is performed 
on the ΔCT and the graphs show the fold change (2-ΔΔCT). (ns = non significant and * = p < 
0.05).  
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 The fact that there is an increase in HAS2 expression in hypoxic MDA-MB-231 MSs 
is a captivating find as HAS2 is a pertinent factor in tumour biology and has been found to be 
involved in potent cancer progression pathways. Recently HAS2 has been described as an 
essential factor for bone metastasis in breast cancer (Okuda et al., 2012). The up-regulation of 
this HA synthesizing enzyme in CSCs is associated with an increased risk of metastasis and 
an enhanced ability of the cells to adhere to immortalized mouse bone microvascular 
endothelial cells (mBMEC) in vitro. These two factors are necessary for metastasis. In their 
studies Okuda et al. used a highly metastatic MDA-MB-231 cell-line derivative known as 
231-BoM. They compared the metastatic abilities of this cell line to that of the conventional 
MDA-MB-231 cell lines. They saw that the highly metastatic 231-BoM cell line had a high 
expression of HAS2 compared to that of the MDA-MB-231 cell line. They showed that HAS2 
was the key element to the metastatic ability. Consequently, observing such an increase in 
HAS2 in the hypoxic MSs of our study reinforces the statements that hypoxia can favour 
cancer progression. This needs of course to be verified. One could investigate the invasive 
abilities of the cells composing these hypoxic MSs by seeding the dissociated MSs in Trans-
well inserts placed over a monolayer of mBMEC. Adherence could be examined by seeding 
the dissociated MSs issued from a hypoxic environment on a monolayer of mBMEC. One 
could also envisage examining whether hypoxia affects ability to survive in vivo, by injecting 
cells from the hypoxic MS into nude mice. It has already been shown that inhibition of HAS2 
in vivo can totally inhibit the progression of primary breast cancer (Udabage et al., 2005). 
These results could further provide proof of the importance of HAS2 in the malignant 
progression of BC. 
 As one of the only established links to the differing responses to the oxygen 
environment within breast CSCs is mediated through the ER-α status, it could be interesting 
to investigate whether this status can also be tied to the high expression of HAS2 in response 
to hypoxia.  
 
4. HAS3 expression in different oxygen conditions 
 
 RT-qPCR analyses aims to detect any possible differences in the transcriptional 
expression of HAS3, another HA synthesising enzyme, that could be caused by a hypoxic 
environment (Fig. 22). 
 MDA-MB-231 MSs show a considerable decrease in HAS3 expression at 7 days 
compared to the level of expression at 4 days, but only in the normoxic condition. The HAS3 
expression in hypoxic MSs does not appear to be affected in such a way. At developmental 
day 4 the level in HAS3 expression seems to be equal between both normoxic and hypoxic 
conditions. After 7 days of growing in the specific oxygen environment there appears to be a 
higher level of expression in the hypoxic MSs, but this is not statistically validated and the 
variability is quite high. Increasing the number of replicates would be of interest. 
 The expression of HAS3 in MCF-7 MSs appears to remain rather constant over the 
course of the chosen times. This is valid for the normoxic and hypoxic MSs. The expression 
of HAS3 at developmental day 4 appears to be higher in the MSs cultured in the low oxygen 
conditions compared to that of the MS cultured in normoxia. This tendency is not statistically 
validated. At developmental day 7, the variability in the hypoxic MSs is quite high, making it 
impossible to draw conclusions. Additional replicates are needed in order to allow an optimal 
analysis of the expression of HAS3 expression in the two different oxygen concentrations. 
 HAS3 does not show any significant differences in expression in response to hypoxia 
in this experimental model, for both MDA-MB-231 and MCF-7 cell lines. In MCF-7 MS 
there does seem to be a tendency of a higher expression of HAS3 in MS cultured in hypoxic 
conditions compared to the normoxic MS. Increasing the number of replicates could reveal 
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Figure 22. Fold change in transcriptional expression of HAS3 in MS cultured for 4 and 7 
days in normoxia or hypoxia. (A and B) represent MDA-MB-231 cell-lines, values were 
obtained from 4 individual replicates. (C and D) represent MCF-7 cell-lines, for which 3 
replicates were used. The values are normalised to actin expression. The statistical analyses 
were carried using a two-way ANOVA with Bonferroni posttests. The analysis is performed 
on the ΔCT and the graphs show the fold change (2-ΔΔCT). (ns = non significant). 
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whether this is a true increase or not. In BC models an increase in HAS3 has not been 
reported yet. In colon carcinomas, on the other hand, an increase in HAS3 and the production 
of HA have been seen to contribute to carcinoma growth and progression (Bullard et al., 
2003). Further studies on the expression of this protein could thus provide researchers with 
vital information, especially for the development of novel treatments. It has already been 
established in vivo that inhibition of HAS2 can limit cancer progression, thus it wouldn’t be 
implausible to envisage inhibition of HAS3 having a similar effect on the malignant 
development of tumours. 
 
5. HYAL1 expression in different oxygen conditions 
 
 The expression of HYAL1 in MDA-MB-231 MSs at 4 and 7 days cultured in different 
oxygen concentrations, namely normoxia and severe hypoxia, was studied at the protein level 
by Western Blot analyses. Due to technical difficulties the sample size is small. Nonetheless, 
the graphs do give an indication of how HYAL1 is expressed in normoxic and hypoxic 
conditions (Fig. 23). 
 In MDA-MB-231 MS the expression of HYAL1 doesn’t seem to vary between 
developmental day 4 and 7 in the normoxic MSs or in the hypoxic MSs. At developmental 
day 4 there doesn’t appear to be any difference in protein expression between normoxia and 
hypoxia. After 7 days in normoxic or hypoxic conditions no particular difference in HYAL1 
expression can be seen either. 
 The expression of this HA degrading enzyme doesn’t appear to develop in MSs 
formed from MCF-7 cell lines over 4 and 7 days whether the cells are exposed to normoxia or 
hypoxia. When comparing the expression of HYAL1 in normoxic and hypoxic MSs at 
developmental day 4 there is no indication of a difference in expression. At developmental 
day 7 the expression of HYAL1 doesn’t appear to be affected by the oxygen concentration.  
 These results give a preliminary indication that the expression of HYAL1 doesn’t 
appear to vary in function of the oxygen concentration in which the MS were cultured. It 
doesn’t seem as if in this particular model either HIFs or hypoxia induced altered metabolism 
can change the level of expression of HYAL1 in MSs exposed to these different oxygen 
concentrations. It would be interesting to ascertain whether the activity of the enzyme shows 
any variations after having been exposed to normoxia or severe hypoxia. There exist different 
classes of HYAL inhibitors that have a crucial role of ensuring that HA degradation is 
fulfilled in a balanced manner. It has been observed that in cancer patients the classes of 
HYAL inhibitors can be expressed in different proportions and can give insight whether the 
patient will have a good outcome or not (Stern, 2005, 2008a). Thus in the future one could 
investigate whether the activity of HYAL1 is altered by hypoxia, and if that is the case the 
proportion of HYAL inhibitors could be examined too. Another avenue that could be explored 
is to see whether hypoxia induces the expression of different HYAL1 isoforms in a breast 
CSC model. In tumours an elevated expression of the wild-type HYAL1 isoform is associated 
with an increased amount of angiogenic inducing fragments. In lung cancer the abundance of 
these splice variants has been studied and found to influence patient outcome (de Sá et al., 
2012).  
 
6. HYAL2 expression in different oxygen conditions 
 
 The effect of the oxygen environment, normoxia compared to severe hypoxia, on 
HYAL2 expression in MSs formed by MDA-MB-231 and MCF-7 cells has equally been 
studied. Two different assays were conducted for this particular study. The western blot 
analysis aims to uncover any differences in the level of expression of HYAL2 that could 
Figure 23. Protein expression of HYAL1 in 
MS cultured in normoxia and hypoxia. (A) 
MDA-MB-231 MSs cultured for 4 and 7 days in 
normoxia and hypoxia. The values are issued 
from 2 individual replicates. (B) MCF-7 MS 
cultured in normoxia and hypoxia for 4 and 7 
days. The values are issued from 2 individual 
replicates. Statistical analysis is not possible due 
to the small sample size of both cell-lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Protein expression of HYAL2 in 
MS cultured in normoxia and hypoxia. (A) 
MDA-MB-231 MSs cultured for 4 and 7 days in 
normoxia and hypoxia. (B) MCF-7 MS cultured 
in normoxia and hypoxia for 4 and 7 days. 
Statistical analysis is not possible due to the 
small sample size. 
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occur in response to a hypoxic environment (Fig. 24). An immunofluorescent staining aims to 
reveal the cellular localisation of the enzyme as well as its level of expression (but this level 
of expression is not quantifiable). 
 The western blot results on HYAL2 expression levels in MDA-MB-231 MSs will be 
described first. The expression of the HA degrading enzyme appears to have a slight tendency 
to decrease from day 4 to developmental day 7 in normoxic conditions. In hypoxic conditions 
the expression of HYAL2 appears to be consistent through the two stages of development. 
When comparing the levels of expression in normoxic and hypoxic conditions at day 4, a 
tendency to a reduction can be seen but the analysis reveals that this reduction is not 
significant. At developmental day 7 the expression level of HYAL2 seems to be equal 
between both normoxic and hypoxic MSs. The immunofluorescent staining of HYAL2 
doesn’t supply us with any consistent results, making it impossible to analyse the results 
acquired from the confocal imaging. This could be a consequence of the fact that the 
fluorescence emitted by the staining of HYAL2 is very faint and requires an amplification of 
the PMT which is not ideal as it decreases the signal to noise ratio. 
 The expression of HYAL2 measured in MCF-7 MSs after exposure to normoxia or 
severe hypoxia will first be characterised based on the western blot analysis and afterwards by 
the immunofluorescent staining. The expression of HYAL2 doesn’t appear to differ over the 
course of the chosen time lapse both in normoxia and hypoxia. The expression at day 4 of the 
MSs culture doesn’t show any difference in expression of the protein of interest between 
normoxic and hypoxic MSs. At day 7 there is equally no significant difference that can be 
observed. As for the MDA-MB-231 MSs, the immunofluorescent staining for HYAL2 is 
particularly faint in the mCF-7 MSs too. The same problems encountered for the analysis of 
the staining of HYAL2 in MDA-MB-231 MSs is valid for the MCF-7 MSs, making it 
impossible to reach any conclusions. 
 In summary, the results of the analysis of HYAL2 expression, although partial and not 
particularly supported by confocal analysis, seem to indicate that this HA degrading enzyme 
does not play a major role in the development of MS under hypoxic vs normoxic conditions. 
In fact, there is no obvious change in either HYAL1 or HYAL2 under the different conditions 
tested.   
 
VI. Conclusion 
 
 The collected data shows that MDA-MB-231 and MCF-7 MSs, which are a model of 
CSCs/TICs, respond to low oxygen conditions in quite different ways. The cells issued from 
the more aggressive ER-α negative cell line, MDA-MB-231, acquire changes in MS 
morphology and in HA metabolism, whereas the less aggressive ER-α positive MCF-7 cell 
line displays accelerated MS formation and growth. 
 
MCF-7 cells 
 
 MSs formed by MCF-7 cell lines didn’t show any significant variations in how they 
metabolise HA after exposure to severe hypoxia. It must be pointed out that the number of 
replicates for this cell line is quite low, and due to many instances of high variability between 
the samples the establishment of conclusions must be done with much precaution. The RT-
qPCR and HA dosage do show that the metabolism of HA could be modified by hypoxia, as 
both HAS proteins have a tendency to increase after seeding in hypoxic conditions. On the 
other hand the dosage of HA shows a slight tendency to a diminished quantity of HA in the 
cellular fraction. This inconsistency between transcript expression and HA dosage could have 
multiple sources. It is possible that the transcripts aren’t translated into proteins, yet if they are 

  37 
one could envisage that the activity of the protein is inhibited by hypoxia. But most 
importantly, as already explained in the results, additional replicates should be performed in 
order to determine whether these tendencies validate themselves or not. 
 The only significant effect that hypoxia had on MCF-7 MS was on the initiation of MS 
formation. Hypoxia induced an increase in the number of MSs formed but only when the 
adherent cell line was pre-incubated for 48 h in hypoxic conditions and after that the cells 
were seeded in hypoxic MS forming conditions. Therefore, it could be of interest to study the 
metabolism of HA in these same circumstances. It would also be of interest to understand the 
mechanisms underlying the improved MS initiation during prolonged hypoxia. The results 
indicate that hypoxia may have a way of preparing the CSC present in the adherent population 
for subsequent survival in low oxygen and anchorage independent conditions. The gathered 
results point out that hypoxia probably doesn’t increase the number of CSC in the adherent 
(“parental”) culture, since no effect was visible in the hypoxic to normoxic conditions of 
culture. In order to further understand why the MS formation is increased in the strictly 
hypoxic conditions, future studies could explore the influence of ER-α and the formation of 
secondary spheres. Additionally one could also attempt to study the expression of stem cell 
markers, such as Notch, Nanog, Oct4 and CD44 shortly after seeding, in order to determine 
whether the different oxygen combinations induce different levels of expressions in the 4 
conditions. Preferably this would be done one day after MS seeding in order to really 
understand how the MS is formed. Performing all of these studies on other cell lines including 
the MDA-MB-231 cell line would of course also be interesting. A minor limitation that 
accompanies studying the actual initiation of MS development is the fact that the cells are 
seeded at rather low densities. This means that there is not much material that can be collected 
at the start of MS formation. The preliminary results conducted by my colleague who 
examined the expression of one of the stem cell markers, CD44, by RT-qPCR in 2-day-old 
MSs show a 5-fold increase in expression. At 4 days the level of expression significantly 
decreases. This indicates that studying the stemness markers as early as possible after seeding 
is crucial. Studies carried out at later periods mean that the MS already have a lower 
proportion of CSC due to the fact that the stem cells will have undergone asymmetric 
divisions, giving rise to a more differentiated progeny.  
 As already evoked in the article published by Harrison et al., for an optimal cancer 
treatment it will be extremely important to determine in what way the ER-α status can 
bequeath CSCs with increased self-renewal abilities or increased dedifferentiation of 
progenitor cells in hypoxic conditions. Based on this status, the treatment approach will have 
to be modified. If the CSCs in ER-α positive cell lines have amplified stemness abilities in 
hypoxic conditions, the anti-angiogenic drugs would not be the appropriate therapy. These 
treatment options could even be catastrophic for the patient as they would favour the CSC 
component of the tumour, which could favour cancer progression. These findings value the 
importance of treating patients in function of the particular cancer subtype their body is 
burdened with (Harrison et al., 2012). The findings of this Master’s Thesis may be 
preliminary but they do contribute to the fact that an ER-α positive cell line has increased 
CSC activity in hypoxic conditions.  This is an important conclusion. The protocol and the 
conditions for MS formation we use are not identical to that of Harrison’s model, but that 
difference in technical approaches may be considered as beneficial, as it shows that even 
under other circumstances the hypoxic effect of increasing CSC activity in MCF-7 cells can 
be observed. 
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 MDA-MB-231 
 
 In the framework of this particular study the MDA-MB-231 cell line appears to have a 
much larger response to hypoxia. MS cultured in hypoxia can develop into larger formations 
over time than those of normoxic cultured MSs. The medium in which the MS are grown is of 
significantly lower pH than that of the normoxic spheres. And very interestingly the 
expression of HAS2 as well as the quantity of HA is increased in hypoxic conditions. One 
could be tempted to imagine that the increase in HAS2 expression in MDA-MB-231 MS 
could be linked to the pH of the medium. The normoxic and hypoxic pH profiles are similar 
between both cell lines, whereas the transcriptional expression of HAS2 is very different 
between the different cell lines. This indicates that the pH is probably not the reason for the 
increased expression of HAS2. 
 The larger size of the hypoxic MS could be explained by increased proliferative or 
self-renewal activity within the MS. This could be verified by analysing the abundance of 
Ki67, a proliferation marker. This is a plausible hypothesis as in the literature hypoxia has 
been associated with increased proliferative activities (Keith & Simon, 2007). As already 
mentioned in the results, if the increased size is due to altered cell-cell or cell-ECM 
interaction it could be a consequence of elevated CD44 expression or an elevated amount of 
HA synthesis which would considerably modify the ECM. The RT-qPCR analysis rules out 
the possibility that increased cell-cell interaction is due to a hypoxic induced elevation of 
CD44 expression. If the increase in MS size is due to increased survival of the cancer cells, 
this could be mediated through the expression of different CD44 splice forms without 
affecting the global level of CD44 expression. The expression of CD44v3 for example has 
been associated with increased tumour cell survival. Once HA has bound to its receptor, then 
Oct4, Sox2 and Nanog form a complex that can activate the production of miR-302. This 
small non-coding RNA can up-regulate survival proteins such as IAP.  
Of course many other proteins could be involved in modifying the adhesion between 
cells and their ECM, for example CD99, α-integrins and collagen 5α1 (Harris, 2002). The 
study of any of these could possibly supply the required information to understand this 
increased MS size in hypoxia. But as they are not relevant to the metabolism of HA, those 
studies were not performed.  
 
HAS2 
 
The other element that could explain the increased MS size and the hypothesized 
favourable cell-cell interactions is an elevated level of HA synthesis. The RT-qPCR analyses 
reveal that there is in fact an increased expression of HAS2 in the hypoxic MDA-MB-231 
MSs. This elevated expression of HAS2 after 7 days in hypoxia would support the theory that 
HA could have an impact on the size of the MS, as an elevated amount of HAS2 indicates that 
there could be a more abundant production of HA. As the expression of HAS2 is based on 
mRNA it would be good to confirm that this elevated HAS2 expression is also valid at the 
protein level. The HA dosage indicates that hypoxia does induce a higher production of HA in 
MSs although not dramatically. The cellular fraction of hypoxic MSs presents a significantly 
increased quantity of HA at developmental day 4, and a tendency to an increased abundance 
at day 7. The HA released into the medium also appears to be higher in the hypoxic MSs. 
These results are partly consistent: there is a slight inconsistency when considering at what 
point in development the increases of HA and HAS2 occur. As already mentioned the 
transcriptional expression of HAS2 shows a tendency to increase at day 4 but is only 
significant at day 7, not as one would have expected. Increased replicates for both assays 
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could elucidate this inconsistency. The increased production of HA in hypoxic MSs could 
explain increased cell-cell interactions allowing this particularly fragile structure to be more 
resistant to the manipulations necessary to analyse them. The interaction that can take place 
between the receptors present on the surface of tumour cells and the HA of the ECM can also 
mediate signalling pathways which could increase the survival of tumour cells and could also 
contribute to the increased size of these hypoxic MSs. One example of such an interaction is 
CD44-bound HA. This interaction can decrease apoptosis and increase tumour cell survival 
via the intermediate of PKC activated Nanog, which could contribute to the increased size of 
these MSs. This very same interaction can also stimulate ERBB2 signalling which inhibits the 
prop-apoptotic protein Bad (Bourguignon et al., 2009; Toole, 2004).  
The expressions of different HASs, especially HAS2, are known to be altered by PDGF-
BB, TGF, glucocorticoids and lactate. Investigating what induces the increase in HAS2 
expression should be a step performed in future studies. The up-regulation could be a direct 
response to hypoxia via one of the HIF proteins but the literature doesn’t evoke the presence 
of HREs in the promoter regions of this HA synthesising protein. It is also possible that the 
expression of HAS2 is indirectly affected by hypoxia. The response could be mediated by the 
altered metabolism that can occur in low oxygen conditions. The presence of lactate-sensitive 
elements in the promoter regions of HAS2 haven’t been documented either. As the MDA-
MB-231 MS medium undergoes significant decrease of the pH under hypoxic conditions, one 
could believe that the cells composing the MS may be in acidosis, or at least have a decreased 
intracellular pH. But due to the fact that the pH measurements of MDA-MB-231 and MCF-7 
MS are similar yet the expression of the HAS enzymes does not follow this pH profile it is 
improbable that it is the pH that induces the difference in HAS2 expression. This does not 
exclude the fact that there may be a higher abundance of lactate within the cells which may 
affect the expression of HAS2. TGF-β is a direct target of HIF-1α, thus the elevation of HAS2 
in response to hypoxia may be an effect of TGF-β. In fibroblasts glucocorticoids have been 
shown to decrease the transcription of the HAS2 gene, meaning that glucocorticoids 
negatively regulate HAS2. Various non-cancer-related studies have uncovered a link between 
hypoxia and glucocorticoids. Hypoxia can increase the levels of glucocorticoid receptors, 
enhancing the sensitivity towards these steroid hormones. The fact that hypoxia has been seen 
to increase the sensitivity to these stress response hormones elicits that it’s not the 
glucocorticoids that induce the up-regulation of HAS2 (Bernert, Porsch, & Heldin, 2011; 
Kodama et al., 2003; Leonard, Godson, Brady, & Taylor, 2013; W. Zhang, Watson, Liu, 
Williams, & Werth, 2000). To better understand this hypoxic response it would be interesting 
to further investigate how the up-regulation of HAS2 expression is mediated.  
 The importance of HAS2 as a crucial factor for metastatic progression is still a 
relatively new concept that should continue to be explored. Studies performed in 2005 are 
amongst the first to tie elevated HAS2 activity to breast cancer progression (Udabage et al., 
2005). In 2011 an article evoked that HAS2 mediates malignant progression by suppressing 
tissue metalloproteases-1 inhibitor (Bernert et al., 2011). This suppression allows the MMPs 
to accomplish the degradation of the ECM which is a necessary step for cellular migratory 
activities, a characteristic of metastatic cells. One year later an article appeared linking the 
HAS2 up-regulation to bone metastasis by breast cancer stem cells (Okuda et al., 2012). The 
high expression of this protein enabled the breast CSCs to interact with tumour associated 
macrophages, which in return secreted a growth factor, PDGF-BB, which stimulates stemness 
pathways such as self-renewal. The interaction between TAMs and CSCs with an elevated 
HAS2 expression is mediated via the abundant presence of CD44 on the TAMs and the 
increased production of HA by the CSCs. The increased production of HA by these CSCs is a 
consequence of the elevated expression level of HAS2. In the CSCs this enhanced expression 
of the HA synthesizing protein also promotes the abilities to adhere and to migrate.  
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 The novel finding that hypoxia increases the expression of the HAS2 gene in MDA-
MB-231 offers some new insight into how hypoxia could contribute to the malignant 
progression of CSCs. As already mentioned further examination must be completed in order 
to better understand how hypoxia can contribute to this increase in HAS2 expression in this 
CSC model. If this adaptation does in fact contribute to malignant progression and is a 
phenomenon present in in vivo tumours it could be possible to use the increased expression to 
the cancer patient’s advantage. Treatment with 4-methylumbelliferone could be an option, as 
this molecule depletes the substrate necessary for HA synthesis and down-regulates the 
mRNA for HAS enzymes (Kultti et al., 2009). Okuda et al. have already established that 
treatment with this small molecule impairs HAS2 mediated in vivo metastasis (Okuda et al., 
2012). It must also be determined whether this gripping response is cell line specific, whether 
it’s dependent on the expression of a particular receptor such as ER-α and whether it is a 
common occurrence in hypoxic breast CSCs. The MCF-7 cell line doesn’t have the same 
response, evoking that it probably isn’t a global breast CSC response to hypoxia. Evidently 
the metastatic properties, enhanced adherence and migratory abilities, that an elevated HAS2 
expression could potentially confer on CSCs must also be tested in this particular model, 
which could back the results published by Okuda et al.  
 Hypoxic effects have been seen to outlast the actual duration of hypoxia. This can be 
caused by epigenetic alterations. Through these alterations the genes up- or down-regulated 
during hypoxia can be maintained in the state of activity that the hypoxic surroundings 
induced. Such epigenetic alteration in response to a certain stress hasn’t solely been reported 
in hypoxic breast CSC: a study on human aortic endothelial cells incubated in hyperglycaemic 
conditions has also revealed that the stress induced response outlasts the duration of the stress 
(El-Osta et al., 2008). This is particularly interesting, as hypoxia is not always chronic in 
tumour masses. The oxygen tension within solid tumours can develop over time and is 
heterogeneous throughout the mass; this means that the cancer cells may succumb to varying 
concentrations of oxygen (Vaupel et al., 2007). This “memory” to stress responses such as 
hypoxia is quite dismaying as a brief encounter with the stressful environment is enough to 
change the cellular mechanisms and offer a cell lasting abilities that could contribute to cancer 
progression. This is only one of the remarkable ways tumour cells are able to overcome and 
take advantage of the biology of the entire organism. 
  
Brief summary 
 
In summary, our findings indicate that hypoxia clearly has an effect on both cell lines 
grown in anchorage independent conditions. This said, the oxygen concentration has very 
different effects in these cell lines: it is only in MDA-MB-231 MSs that the metabolism of 
HA is altered. The MCF-7 cells see an increase in the number of MSs formed under strictly 
hypoxic conditions, when both the pre-treatment and the MS seeding are carried out in low 
oxygen tensions, indicating that hypoxia may prepare the CSCs to survive in low oxygen 
conditions (epigenetic phenomenon?). The fact that MDA-MB-231 cells see an increase in 
HA quantities and in HAS2 expression at the RNA level still needs to be further elaborated, 
but this preliminary result indicates that this may be a novel pathway to how hypoxia 
contributes to the malignant progression of cancer. 
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